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Abstract Photodynamic therapy (PDT) has emerged as a
promising alternative to conventional cancer therapies such
as surgery, chemotherapy, and radiotherapy. PDT com-
prises the administration of a photosensitizer, its accumu-
lation in tumor tissue, and subsequent irradiation of the
photosensitizer-loaded tumor, leading to the localized
photoproduction of reactive oxygen species (ROS). The
resulting oxidative damage ultimately culminates in tumor
cell death, vascular shutdown, induction of an antitumor
immune response, and the consequent destruction of the
tumor. However, the ROS produced by PDT also triggers
a stress response that, as part of a cell survival mecha-
nism, helps cancer cells to cope with the PDT-induced
oxidative stress and cell damage. These survival pathways
are mediated by the transcription factors activator protein
1 (AP-1), nuclear factor E2-related factor 2 (NRF2),
hypoxia-inducible factor 1 (HIF-1), nuclear factor κB
(NF-κB), and those that mediate the proteotoxic stress
response. The survival pathways are believed to render
some types of cancer recalcitrant to PDT and alter the
tumor microenvironment in favor of tumor survival. In this
review, the molecular mechanisms are elucidated that occur
post-PDT to mediate cancer cell survival, on the basis of which
pharmacological interventions are proposed. Specifically, phar-
maceutical inhibitors of the molecular regulators of each sur-
vival pathway are addressed. The ultimate aim is to facilitate the
development of adjuvant intervention strategies to improve
PDT efficacy in recalcitrant solid tumors.
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1 Introduction
The standard treatments for solid tumors include surgery, che-
motherapy, and/or radiotherapy. However, these treatments are
often associated with high morbidity and are often unsuccess-
ful. Consequently, alternative modalities must be devised to
treat solid tumors with equal or improved clinical outcomes
but in a more patient-friendly manner. Photodynamic therapy
(PDT) is an alternative treatment modality that entails the sys-
temic or topical administration of a photosensitizing agent
followed by local irradiation of the photosensitizer-loaded tu-
mor tissue with light of the appropriate wavelength tomatch the
photosensitizer absorption. Irradiation causes the photosensitiz-
er to first enter a short-lived excited singlet state that can tran-
sition to a long-lived excited triplet state [1]. Triplet state pho-
tosensitizers can transfer energy to molecular oxygen to yield
singlet oxygen (1O2) by electron transfer electrons to form su-
peroxide anion (O2
•−) and hydroxyl radicals (HO•). These reac-
tive oxygen species (ROS) and their derivatives (such as lipid
peroxides) subsequently oxidize biomolecules in the
photosensitized tissue, causing cellular oxidative stress, tissue
anoxia and tumor starvation due to ROS-mediated shutdown of
tumor vasculature, and an antitumor immune response. Collec-
tively these events contribute to cellular demise and removal of
the tumor [2]. PDT provides important benefits compared to
surgery, radiotherapy, and chemotherapy in that it is minimally
invasive or even noninvasive and can be performed locally
causing only minor damage to healthy tissue [3–5]. Moreover,
PDT has been associated with increased life expectancy in can-
cer patients [6], is cost-effective [4, 7, 8], generally does not
require extended therapeutic follow-ups, and can easily be re-
peated in case of cancer recurrence. The latter is often difficult
or impossible with the conventional therapies.
PDT has proven to be highly effective in the treatment of
various types of cancer (Fig. 1a) [9–11, 13]. However, bladder
and nasopharyngeal tumors exhibit poor complete response
rates following PDT (Fig. 1a) [14–16]. For a variety of esoph-
ageal lesions and early-stage central lung cancers, the results
differ greatly depending on the center administering the treat-
ment and the exact type of PDT procedure performed [10, 11].
With respect to the treatment of nonresectable extrahepatic
cholangiocarcinomas, PDT has shown promising results by
considerably improving the median survival of patients
(Fig. 1b) [12], but the therapy is currently palliative and not
curative.
The therapeutic failure in some of these cancer types likely
stems from the use of photosensitizers with suboptimal optical
and biochemical properties, inferior photosensitizer pharma-
cokinetics and/or pharmacodynamics, and variations in the
tumor phenotype and genotype, which may positively influ-
ence tumor cell survival following PDT-induced oxidative
damage [17].While many investigators are looking at improv-
ing or developing new PDT strategies using chemistry or
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engineering approaches, relatively little research has been per-
formed on the biology behind the therapeutic resistance, in-
cluding the survival mechanisms that are triggered in cells to
cope with the consequences of PDT. Several transcription fac-
tors have been identified that mediate cell survival following
PDT (or approaches with similarities to PDT such as ultravi-
olet light irradiation). These include the members of the acti-
vating protein 1 (AP-1) transcription factor family, nuclear
factor E2-related factor 2 (NRF2), hypoxia-inducible factor
1 (HIF-1), nuclear factor κB (NF-κB), heat shock factor 1
(HSF1), and transcription factors associated with the unfolded
protein response (UPR).
In this review, a complete overview is provided of
these pathways in terms of the activation mechanism,
downstream biochemical and (patho)physiological ef-
fects, current state of knowledge regarding the involve-
ment of these pathways in promoting tumor cell surviv-
al before and after PDT, as well as potential inhibition
strategies for these pathways that can be used to in-
crease the therapeutic efficacy of PDT.
2 Photodynamic and biochemical activation
of survival pathways
2.1 ROS production through photosensitizer excitation
PDT encompasses laser or light irradiation of the tumor-
localized photosensitizer at a wavelength that corresponds
to the photosensitizer’s main absorption peak in the longer
wavelength range of the visible spectrum (typically red light
that is able to deeply penetrate tissue). Irradiation of a
photosensitizer with light of a resonant frequency leads to
photon absorption by the photosensitizer, resulting in the
transition of an electron from the ground state (S0) to an
energetically higher but unstable first excited state (S1)
[18]. In most molecules, the S1 electron rapidly (typically
in the order of a few nanoseconds) undergoes vibrational
relaxation and, in some instances, molecular relaxation dur-
ing its decay to S0 [18], producing heat and emission of a
photon (fluorescence), respectively. However, S1 electrons in
photosensitizers generally exhibit a strong tendency to un-
dergo intersystem crossing, in which the energy of the pho-
ton is redistributed over two unpaired electrons with the
same spin orientation. From this lower energy yet longer
lived triplet (T1) state, electrons can react with molecular
oxygen (O2) in their decay to S0. Two types of photochem-
ical reactions can proceed from the T1 state: type I reactions
are characterized by electron transfer from the photosensitiz-
er to O2, yielding O2
•– [18–20]. O2
•– has a relatively low
reactivity but a long lifetime (several seconds) [21] and
mainly acts as a precursor radical from which secondary
and tertiary radicals are formed in biological systems [22].
Type II reactions are the result of energy transfer from the T1
electrons to O2, resulting in the production of highly reactive
1O2 [18, 23]. The strong reactivity of
1O2 toward lipids,
nucleic acids, proteins, and other biochemical substrates is
reflected by its short biological half-life (3×10−9 s) and the
small area of effect in viable cells (2–4 ×° 10−6 cm2) [24].
Additionally, since the ground state of O2 is the triplet state,
only a minor amount of energy (94.5 kJ mol−1) is required
for excitation to the singlet state, equivalent to the en-
ergy of a photon with a wavelength of 850 nm or
shorter [18].
Fig. 1 a Overview of clinically obtained complete response rates with
PDT of actinic keratoses (AK), skin cancers (SC), early stage central lung
cancers (ECLC), esophageal malignancies (EM), nasopharyngeal
carcinoma (NPC), and bladder cancer (BC). SC included (nodular)
basal cell carcinomas and squamous cell carcinomas [9]. EM included
Barrett’s esophagus, low-grade dysplasia, high-grade dysplasia, and
esophageal cancer [10]. BC included carcinoma in situ, recurrent
superficial bladder cancer, and early stage lesions [11]. Complete
response rates were averaged using the longest time interval in each
study. b Average of the median survival time postdiagnosis of
extrahepatic cholangiocarcinoma patients treated with PDT or left
untreated (control) [12]. Adjuvant treatments, type of photosensitizer,
light source, and light dose were not taken into account, as a result of
which no statistical analyses were performed
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2.2 Mechanisms of cytotoxicity
2.2.1 PDT-induced oxidative stress
The production of ROS occurs during irradiation of the pho-
tosensitizer. Although these primary ROS are short-lived,
there is ample evidence that PDT induces prolonged oxidative
stress in PDT-treated cells [25, 26]. The post-PDT oxidative
stress stems from (per)oxidized reaction products such as
lipids [26] and proteins [27] that have a longer lifetime and,
in addition to acutely generated ROS, depletion of intracellu-
lar antioxidants [28] and, hence, further exacerbation of al-
ready perturbed intracellular redox homeostasis.
The generation of ROS and oxidative stress by PDT leads
to the activation of three distinct tumoricidal mechanisms. The
first mechanism is based on the direct toxicity of
photoproduced ROS, which oxidizes and damages biomole-
cules and affects organelle and cell function. For example, 8-
hydroxydeoxyguanosine is a reaction product of ROS with
guanosine [29] and may contribute to the induction of DNA
damage by PDT [30–38]. Furthermore, 8-oxo-7,8-dihydro-2′-
guanosine is a product of RNA oxidation reactions that leads
to impaired RNA-protein translation [39, 40].
With respect to phospholipids, linoleic acids are prominent
targets for ROS-mediated peroxidation [41], yielding 9-, 10-,
12-, and 13-hydroperoxyoctadecadienoic acids as specific
products of 1O2-mediated linoleic acid oxidation [42]. Other
membrane constituents such as cholesterol, α-tocopherol, al-
dehydes, prostanes, and prostaglandins are susceptible to ox-
idation by type I and type II photochemical reaction-derived
ROS [41, 43–46]. The (per)oxidative modifications of phos-
pholipids and membrane-embedded molecules by ROS lead
to changes in membrane fluidity, permeability, phase-
transition properties, and membrane protein functionality
[47–60]. Since many photosensitizers are lipophilic, the oxi-
dation of membrane constituents by PDT is likely a prominent
cause of cell death.
In addition to nucleic acids and lipids, most protein resi-
dues are also susceptible to oxidation by type I and type II
photochemical reaction-derived ROS, which can potentially
lead to rupture of the polypeptide backbone as a result of
peptide bond hydrolysis, main chain scission, or the formation
of protein-protein cross-links [61]. Specific amino acids such
as histidine, tryptophan, tyrosine, cysteine, and methionine
that may be involved in the active sites of enzymes can be
oxidized. Proteins that are most abundantly modified by PDT-
generated ROS include proteins involved in energy metabo-
lism (e.g., α-enolase, glyceraldehyde-3-phosphate dehydro-
genase), chaperone proteins (e.g., heat shock proteins
(HSP)70 and 90), and cytoskeletal proteins (e.g., cytoplasmic
actin 1 and filamin A α) [62]. Besides detrimental effects on
protein function, oxidative modification of these biologically
essential substrates disrupts the normophysiological redox
state of cells, leading to oxidative stress and, in case of exces-
sive damage or stress, cell death via necrosis, apoptosis
(reviewed in [63]), or necroptosis [64], depending on which
intracellular substrates are most affected by ROS (reviewed in
[65]).
Surviving cells may activate adaptation mechanisms in or-
der to (1) restore the intracellular redox homeostasis (antiox-
idant response), (2) activate a stress response that aids in sur-
vival or stimulates apoptosis (immediate early stress re-
sponse), and (3) facilitate in refolding or degradation of
carbonylated proteins (proteotoxic stress response). Autopha-
gy as a result of mitochondrial or ER stress may prevent apo-
ptotic cell death and thereby constitutes a survival mechanism
in sublethally damaged tumor cells following PDT [66].
2.2.2 PDT-induced hypoxia
The second tumoricidal mechanism of PDT involves the in-
duction of local hypoxia in the irradiated tumor bulk. The
acute induction of hypoxia is a result of O2 depletion in con-
sequence to the O2→
1O2 or O2
•– conversion and subsequent
oxidation of biomolecules during PDT [67] and the shutdown
of tumor vasculature after PDT [68]. The majority of systemic
first- and second-generation photosensitizers localize primar-
ily in endothelial cells as well as tumor cells that line the tumor
vasculature after short drug-light intervals [69, 70], defined as
the time between photosensitizer administration and light de-
livery. Endothelial photosensitization in particular is associat-
ed with vasculature-damaging effects [71–74] that translate to
a favorable therapeutic outcome. Prolonged hypoxia due to
the destruction of intratumoral vasculature was found to be
crucial in the massive induction of cell death following PDT
as a result of thrombosis, hemostasis, and cessation of oxygen
and nutrient supply (reviewed in [68]). A state of hypoxia or
even anoxia reduces the ability of cells to generate ATP by
oxidative phosphorylation [75]. As will be reviewed here,
hypoxia causes cells to resort to ATP production through an-
aerobic metabolism to sustain cell function and restore ho-
meostasis and promote angiogenesis to resolve the hypoxic
conditions. Cells that are incapable of sustaining ATP produc-
tion anaerobically due to extensive oxidative stress undergo
necrotic cell death (an ATP-independent mode of cell death),
which is the strongest trigger for the third tumoricidal mech-
anism: the antitumor immune response.
2.2.3 PDT-induced antitumor immune response
The antitumor immune response, which is triggered by a form
of sterile inflammation, constitutes an important process in the
post-PDT removal of the treated malignancy. Various studies
in mice have shown that activation of the immune system after
PDT is necessary for complete eradication of the tumor [76,
77]. The tumor cell death that occurs directly from
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photochemical damage or as a result of vascular shutdown-
mediated hypoxia/anoxia and hyponutrition is the key precur-
sor event for the antitumor immune response.
The PDT-treated cancer cells die as a result of necrosis,
apoptosis [78], necroptosis [64], and/or autophagy [79]. In
all modes of cell death, intracellular molecules are released
that, following their release, act as so-called damage-associat-
ed molecular patterns (DAMPs) [80]. The released molecules
also comprise tumor-associated antigens (TAAs) that are oth-
erwise shielded from recognition by immune cells and hence
are nonimmunogenic until released [81]. Accordingly, the ex-
tracellular DAMPs and TAAs alert cells of the innate and
adaptive immune system of impending cellular demise and
the presence of malignant tissue, respectively, and conse-
quently trigger a sterile immune response aimed at removing
the PDT-treated tumor [82]. A major advantage of the PDT-
triggered oncoimmunological pathways is that these pathways
can trigger an antitumor immune response mediated by
antigen-specific T-cells against distant tumor cells that were
not subjected to PDT (referred to as abscopal effects) [83, 84].
3 Survival pathways activated in tumor cells
post-PDT
The tumor cells that are subjected to sublethal oxidative dam-
age or that are located in tumor regions not affected by vas-
cular shutdown can activate cell survival mechanisms that
have been proposed to lie at the basis of therapeutic recalci-
trance [17]. We postulate that tumor cell survival following
PDT is attributable to at least five interconnected pathways.
These pathways include (1) an antioxidant response mediated
by NRF2; (2) a hypoxic survival response mediated by HIF-1;
(3) a proinflammatory and angiogenic response mediated by
NF-κB; (4) a proteotoxic stress response mediated by tran-
scription factors HSF1, X-box binding protein 1 (XBP1), ac-
tivating transcription factor (ATF) 6, and ATF4; and (5) an
acute stress response mediated by apoptosis signal-
regulating kinase 1 (ASK1), its downstream mitogen-
activated protein kinase (MAPK) that targets c-Jun N-terminal
kinase (JNK) and p38MAPK, and the transcription factors of
the activator protein 1 (AP-1) family. An overview of the
survival pathways is provided in Fig. 2. The following sec-
tions will address each of these pathways individually and
discuss their potential activation mechanism by PDT, their
downstream effects and function, their participation in the
PDT response, as well as possible inhibition strategies to re-
duce their cytoprotective effects and improve the tumoricidal
efficacy of PDT.
Some of the survival mechanisms operate by their consti-
tutive activation in cancer cells before PDT, which then pre-
vent cell death following PDT. In other cases, the activation
of the survival mechanisms is induced by PDT and may
consequently translate to prolonged survival in cells that
were subjected to sublethal oxidative damage. Despite the
fact that the ROS produced by PDT are generally short-
lived (Section 2.1), their secondary metabolites (e.g.,
(per)oxidized proteins, protein residues, and lipids) can
sustainably disrupt cellular redox states in the tumor tis-
sue [26, 28, 62]. This may cause a second wave of cell
Fig. 2 Reactive oxygen species (ROS)-induced activation of cell
survival-related signal transduction pathways in cancer cells following
photodynamic therapy (PDT). PDT induces vascular shutdown and
oxidation of proteins, which results in hypoxia and proteotoxic stress,
respectively. ROS directly trigger the NRF2-mediated antioxidant
response and the ASK1-induced immediate early stress response.
Hypoxia and ROS are both involved in the activation of the NF-κB
inflammatory response and the HIF-1 hypoxic response. The
proteotoxic stress response is characterized by the activation of several
transcription factors (TF), including HSF1, ATF4, ATF6, and XBP1
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death, whereby the oxidatively stressed but still viable tumor
cells ultimately perish via programmed mechanisms due to the
inability to restore cell function and homeostasis [85].
The molecular pathways discussed in this chapter are gen-
erally involved in shifting the balance toward cell survival,
although in some contexts, these pathways may also stimulate
cell death. It should be pointed out that the exact activation
mechanisms of the signaling pathways have generally not
been studied in the context of PDT, but rather in the context
of oxidative stress, ROS, hypoxia, or other pathways. How-
ever, since many of these activators have also been implicated
in PDT, we propose that these activation mechanisms can also
be applied to PDT-treated cells to explain various experimen-
tal findings that support a survival-promoting role for these
pathways.
3.1 The NRF2 pathway
During PDT, ROS are formed that oxidize a plethora of bio-
molecules and lead to their structural modification and dys-
function. When this occurs on an extensive scale, the oxida-
tive stress culminates in acute cell death. However, when in-
sufficient ROS are produced to induce acute cellular demise,
cells will suffer from prolonged oxidative stress whereby the
intracellular antioxidative capacity is reduced in the absence
of full execution of cell death pathways. Upon exposure to
sublethal oxidative stress, cells attempt to restore redox ho-
meostasis through the upregulated production of antioxidants,
detoxifying enzymes, as well as phase III drug transporters to
mediate the efflux of potentially harmful oxidation products
[86, 87].
NRF2 is the transcription factor that initiates this antioxi-
dant response, a process that may be important in PDT-
surviving tumor cells since it enables the cells to restore intra-
cellular redox homeostasis in a post-PDT microenvironment
and enhances the chances for long-term survival. Although
NRF2 is a putative repressor of tumorigenesis by protecting
cells by detoxifying ROS and ameliorating other stressors that
cause malignant transformation [88], the cytoprotective ef-
fects of NRF2 are likely to contribute to reduced apoptosis-
and therapy resistance in tumor cells. Moreover, NRF2 and its
downstream gene products are constitutively overexpressed in
many tumor types [89], especially in malignant tissues that
had been exposed to the carcinogenic effects of oxygen, air
pollution, and tobacco smoke [90], thereby predisposing tu-
mor cells to tolerate PDT-induced oxidative stress to a greater
extent. In a review on the role of NRF2 in oncogenesis,
Gañán-Gómez et al. proposed that NRF2 deregulation in tu-
mor tissue could be attributed to mutations and loss of hetero-
geneity; hormonal and onocogenic signaling; epigenetic, post-
transcriptional, and posttranslational abnormalities; deregula-
tion of autophagy, as well as induction by drugs [90]. Conse-
quently, tumorigenesis is stimulated by aberrant NRF2
signaling that translates to enhanced cell growth, promotion
of metastasis, increased survival, and chemoresistance [90].
Accordingly, the following sections discuss the activation
mechanism of NRF2 by ROS (Section 3.1.1), the downstream
gene targets of NRF2 and their function (Section 3.1.2), the
evidence for the participation of the NRF2 pathway in the
survival of tumor cells following PDT (Section 3.1.3), as well
as potential NRF2 inhibition strategies to reduce tumor cell
survival following PDT (Section 3.1.4).
3.1.1 Activation mechanism of NRF2
NRF2 is a bZIP transcription factor that is constitutively
expressed in most cells and tissue types [91–93]. Under
normoxic conditions, NRF2 associates with Kelch-like
ECH-associated protein 1 (KEAP1) that is bound to the cyto-
plasmic cytoskeleton and therefore sequesters NRF2 in the
cytosol [94, 95]. Moreover, KEAP1 binds Cullin-3 that forms
a scaffold for E3 ubiqui t in l igases to faci l i ta te
polyubiquitination and subsequent proteasomal degradation
of NRF2. Thus, under normoxic conditions, the antioxidant
stress response is inactivated by high levels of cytosolic reten-
tion and degradation of NRF2 (reviewed in [86]). During ox-
idative stress, the NRF2-binding domain of KEAP1 is oxi-
dized at Cys273 and Cys288, resulting in impaired KEAP1
binding to NRF2 [96]. Consequently, free NRF2 accumulates
in the cytoplasm where it is activated by oxidation at Cys183,
after which it is able to translocate to the nucleus [86]. Addi-
tional phosphorylation of NRF2 at serine (Ser)40 by p38α/β
and/or JNK1, which are also induced by PDT (Section 3.4),
may also play a role in the dissociation of the NRF2-KEAP1
complex or the prevention of NRF2-KEAP1 binding [97–99].
Once in the nucleus, NRF2 dimerizes with members of the
AP-1 family, such as JUN and musculoaponeurotic fibrosar-
coma oncogene homologue (MAF) subfamily proteins [100,
101], and binds to antioxidant response element (ARE) se-
quences to induce the transcription of antioxidant genes. An
overview on the activation mechanisms of NRF2 and down-
stream effects is presented in Fig. 3. An elaborate review on
the activation mechanisms of NRF2 is provided in [86].
3.1.2 Downstream effects of the NRF2 pathway
The products of NRF2 target genes are involved in the syn-
thesis and redox cycling of antioxidants as well as the removal
of potentially harmful oxidation products. The NRF2/AP-1
target genes include NAD(P)H:quinone oxidoreductase 1
(NQO1) and NQO2, heme oxygenase-1 (HO-1, HMOX1),
glutamate-cysteine ligase (GCL), microsomal epoxide hy-
droxylase (EH-1), glutathione S-transferases (GSTs),
sulfiredoxin 1 (SRXN1), and carboxylesterase 1A1
(CES1A1) [102]. EH-1 neutralizes epoxides, whereas NQO1
and NQO2 reduce oxidized quinones to prevent further cell
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damage by these reactive species [103, 104]. CES1A1 hydro-
lyzes esters and thioesters [105]. HO-1 neutralizes certain
types of ROS directly as well as oxidized metabolites (lipid
radicals) indirectly by producing the antioxidant molecule bil-
irubin from heme [106, 107]. Moreover, proteins involved in
the reduction and reactivation of radical scavengers such as
glutathione (GSH) and peroxiredoxins are upregulated by
NRF2, including GCL (subunits GCLC and GCLM), GSTs,
and SXRN1 [108, 109]. NRF2 further upregulates ATP-
binding cassette subfamily C (ABCC) 2, 3, 4, and 6 (also
known as multidrug resistance proteins (MRPs)) and the mul-
tidrug efflux pump ATP-binding cassette subfamily G mem-
ber 2 (ABCG2), which mediate efflux of organic anions and
glutathionylated, glucuronidated, and/or sulfated
(bio)molecules (reviewed in [102, 110–112]). Such biomole-
cules are the products of oxidative stress that are potentially
harmful by themselves [102]. MRPs may therefore be crucial
for the detoxification of tumor cells that have survived the
initial PDT-induced ROS attack and can aid in restoring the
intracellular redox balance.
HO-1 in particular has been linked to cancer cell survival
following PDT. Besides being upregulated by NRF2, HO-1
(encoded by theHMOX1 gene) is upregulated by HIF-1 [113],
which is also induced by PDT (Section 3.3). The function of
HO-1 is to convert mitochondrially produced heme into car-
bon monoxide (CO) and biliverdin, of which the latter is re-
duced by biliverdin reductases to bilirubin [114]. Bilirubin
scavenges peroxidized lipids [115, 116] and may significantly
contribute to tumor cell survival following PDT by
terminating lipid oxidation chain reactions. Furthermore, at
low concentra t ions , CO possesses vasodi la t ing,
proangiogenic, anti-inflammatory, and antiapopotic proper-
ties, which can contribute to angiogenesis, tumor survival,
and tumor regeneration in vivo [117, 118]. Although the deg-
radation of heme to bilirubin also liberates Fe2+ that contrib-
utes to a prooxidant state, the release of Fe2+ by HO-1 was
found to concomitantly increase the transcription of ferritin
[119], which chelates and neutralizes free Fe2+ [120].
Another major pathway augmented by NRF2 is the GSH
synthesis pathway, which yields an effective redox machinery
aimed at scavenging ROS and neutralizing reactive interme-
diates such as oxidized protein residues (by glutathionylation)
[121]. Synthesis of the GSH tripeptide occurs by ligation of L-
glutamate and L-cysteine by GCL and addition of glycine by
GSH synthetase. GSH can reduce ROS through oxidation of
its thiol moiety (GSH→GS•), after which the reactive thiol is
neutralized by GS-GS homodimerization (GSSG) with anoth-
er GS• through disulfide bridge formation. Recycling of
GSSG to GSH is catalyzed by GSSG reductase (reviewed in
[121]). GSH can also react with oxidized cysteine residues,
resulting in protein glutathionylation and subsequent cellular
efflux via proteins of the MRP family [110]. Moreover, GSTs
of different classes are upregulated by NRF2, which are re-
sponsible for the glutathionylation of oxidized proteins
resulting in increased MRP transporter-mediated efflux of
glutathionylated peptides [122]. Another role for GSTs is to
inhibit molecular constituents in the ASK1 pathway, including
ASK1 (by GSTM), JNK (by GSTP/GSTA), and tumor
Fig. 3 The activationmechanism ofNRF2 and downstream transcription
events. Under normophysiological conditions, NRF2 is sequestered in an
inactive cytoplasmic complex with KEAP1. Under oxidative stress
conditions, ROS mediate the oxidation (ox) of essential cysteines in the
NRF2-binding domain of KEAP1, which deters complex formation.
NRF2 can be additionally oxidized at Cys183 by ROS under
prooxidative conditions, which enables its nuclear translocation.
Moreover, ROS can activate the ASK1 pathway, in which the MAPKs
JNK1 and p38α/β phosphorylate (P) NRF2 at Ser40, leading to its
activation. Subsequently, NRF2 translocates to the nucleus where it
dimerizes with AP-1 transcription factors (Section 3.4.2) and initiates
the transcription of antioxidant enzymes (e.g., glutathione synthesis)
and multidrug transporters (ABCC2, ABCC3, ABCC4, ABCC6 and
ABCG2)
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necrosis factor receptor associated factor 2 (TRAF2) (by
GSTP), although the inhibitory efficacy decreases upon
oxidative stress [122]. This may prevent prolonged ac-
tivation of the ASK1 pathway and could stimulate cell
survival as is discussed in Section 3.4. In sum, the
activation of NRF2 is essential for the production of
proteins involved in GSH synthesis and redox regula-
tion, as well as the neutralization of oxidative com-
pounds and their cellular efflux.
3.1.3 Role of the NRF2 pathway in PDT
Although NRF2 activation by ROS is well-established, its
activation by PDT has been sparsely investigated. Nuclear
translocation and thus activation of NRF2 was observed by
Kocanova et al. in human bladder cancer (T24) cells and hu-
man cervical cancer (HeLa) cells following hypericin-PDT
[85]. Furthermore, NRF2 target genes were overexpressed in
various cancer cells after PDT, which include HO-1 [123],
GCLC and GCLM subunits of GCL [124], NQO1 [124,
125], and ABCG2 [111]. The inhibition of p38MAPK (p38α
and p38β, Section 3.4.2) with PD169316 reduced HO-1 mes-
senger RNA (mRNA) levels and increased the susceptibility
of T24 cells to PDT [85]. These findings indicate that NRF2 is
activated following PDT, that p38MAPK-mediated phosphory-
lation enhances the activity of NRF2 post-PDT, and that the
expression of HO-1 by NRF2 is cytoprotective. Several re-
ports have corroborated HO-1-mediated cytoprotection fol-
lowing PDT [123, 126, 127]. However, HO-1 was also found
to be induced by aminolevulinic acid (ALA) prior to PDT
[111], and targeted knockdown of HO-1 has been related to
reduced intracellular protoporphyrin IX (PPIX) accumulation
[128], indicating that HO-1 can both inhibit PS accumulation
as well as reduce the PDT response. Interestingly, of the MDR
proteins induced by NRF2, at least ABCG2 has been
confirmed to facilitate cytoprotection against PDT by
mediating the cellular efflux of photosensitizers PPIX,
pyropheophorbide A, and benzoporphyr in der i -
v a t i v e monoac i d r i ng A [129 ] bu t no t meso -
tetrahydroxyphenylchloride and porfimer sodium [130].
3.1.4 Inhibition strategies for NRF2 and its downstream
targets
Retinoic acid has been identified as an inhibitor of NRF2 in
human mammary carcinoma (MCF-7) cells transfected with
an ARE-luciferase reporter construct. Retinoic acid abolished
the expression of genes with ARE sequences in their promoter
regions [131] but did not affect the nuclear translocation or
degradation of NRF2. Rather, retinoic acid inhibited the func-
tion of NRF2 by activating retinoic acid receptorα (RARα) in
the nucleus. RARα sequesters NRF2 in the nucleus, thereby
inhibiting the association between NRF2 and ARE sequences
[131] (Table 1). Unfortunately, not much is known about the
binding specificity of retinoic acid, nor has retinoic acid or any of
its analogs been studied in the context of PDT. Nevertheless,
retinoic acid and its analogs are also involved in the inhibition
of AP-1 transcription factors (Section 3.4.2.2 Prolonged down-
stream effects of ASK1 activation), which constitute the main
dimerization partners for NRF2. Thus, PDTwith RARα activa-
tors may potentially enhance the cytotoxic effects of PDT by
inhibiting both AP-1 and NRF2 survival signaling.
In addition to inhibiting NRF2-mediated gene expression,
the downstream gene products of NRF2, such as HO-1 and
members of the GSH antioxidant machinery, may also be
successfully inhibited by small molecular compounds (e.g.,
Zn-protoporphyrin IX (ZnPP) [132, 165], Table 1).
Inasmuch as HO-1 catalyzes the degradation of heme into
the antioxidants bilirubin and CO, inhibition of HO-1 with
ZnPP during PDT is expected to enhance tumoricidal effi-
cacy. Indeed, HO-1 inhibition with 2.5 μM ZnPP consider-
ably reduced cell viability following porfimer sodium-PDT
in both human (MDAH2774) and murine (C26) colon car-
cinoma cell lines. The addition of bilirubin or CO could not
rescue cells from PDT-induced cell death upon HO-1 inhi-
bition, suggesting a more elaborate role of HO-1 in the
survival of tumor cells than merely the synthesis of antiox-
idants [123]. Similar results with HO-1 inhibition were ob-
tained in WM541Lu human melanoma cells subjected to
ALA-PDT, where the addition of anti-HO-1 siRNA (24 h
prior to PDT) or tin-PPIX (SnPP [133]) increased the sus-
ceptibility of these cells to PDT [126]. SiRNA-mediated
knockdown of HO-1 also increased the susceptibility of
UM-UC-3 (but not T24, KU7, UM-CU-2, and UM-CU-4)
human urothelial carcinoma cell lines to ALA-PDT [128].
With respect to other NRF2-upregulated antioxidants,
Kimani et al. tested several inhibitors of the glutathione
redox system and ROS scavenging enzymes (superoxide
dismutases (SODs) and catalase) to increase the efficacy of
disulfonated aluminum-phthalocyanine-PDT of MCF-7
breast cancer cells [166]. Diethyl-dithiocarbamate (DDC)
and 2-methoxyestradiol (2-ME) were used as inhibitors of
Cu-SOD/Zn-SOD [167] and Mn-SOD (although 2-ME has
been shown not to inhibit Mn-SOD [134]), respectively
(Table 1). L-Buthionine sulfoximine (BSO) was used as an
inhibitor of GCL (glutathione synthesis [135]) and 3-amino-
1,2,4-triazole (3-AT) as an inhibitor of catalase [136]
(Table 1). All inhibitors were efficient in exacerbating
PDT-induced apoptosis. The strongest effects were observed
when a combination of BSO with either 3-AT or 2-ME was
used, which achieved similar results as when all the inhibi-
tors were combined. This suggests that the inhibition of
H2O2 scavenging (by inhibition of catalase) and •OH scav-
enging (by inhibition of GCL and glutathione synthesis) and
inhibition of the enzymatic dismutation of O2
•– to H2O2 (by
SODs) significantly increase the susceptibility of cells to
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PDT [166]. In conclusion, the preemptive inhibition of both
the bilirubin and glutathione synthesis pathways revealed a
protective effect of these pathways on the survival of tumor
cells following PDT, altogether indicating that the NRF2
pathway counteracts the cytotoxicity of PDT.
3.1.5 Concluding remarks
NRF2 is the main trigger for the antioxidant stress response
that restores the intracellular redox status toward
normophysiological levels in PDT-surviving cells. The
Table 1 Overview of pharmacological agents that are used for the inhibition of select targets in PDT-induced cytoprotective pathways
Pathways Target Inhibitor Mechanism Reference
NRF2 NRF2 Retinoic acid (and analogs) Inhibition of DNA- binding due to sequestration by RARα [131]
NRF2 HO-1 ZnPP Nonreversible antagonist [132]
NRF2 HO-1 SnPPIX Nonreversible antagonist [133]
NRF2 Cu-SOD/Zn-SOD DDC Chelation of Cu(II) and Zn(II) [167]
NRF2 Mn-SOD 2-ME Does not inhibit Mn-SOD but increases superoxide levels [134]
NRF2 GCL BSO Nonreversible antagonist [135]
NRF2 Catalase 3-AT Nonreversible antagonist [136]
NF-κB RELA (NF-κB) Parthenolide Alkylation at Cys38, inhibition of DNA binding [137]
NF-κB NF-κB Panepoxydone Inhibition of IκB phosphorylation [138]
NF-κB NF-κB Bay 11-7082 Inhibition upstream of IKK [139]
NF-κB NF-κB DHMEQ Inhibition of DNA binding and nuclear localization [140]
NF-κB NF-κB α-Ketoglutarate Reactivation of PHD proteins [141]
NF-κB COX-2 NSAIDs (e.g., ibuprofen, celecoxib) Reversible antagonist [142]
NF-κB STAT3 STA-21 Inhibition of DNA binding [143]
NF-κB STAT3 WP1066 Dephosphorylates STAT3 and causes nuclear export [144]
NF-κB Survivin LY218130B RNAi [145]
NF-κB Survivin YM155 Inhibition of transcription [145]
NF-κB Survivin Terameprocol (EM1421) Inhibition of transcription [145]
NF-κB IL-6/sIL-6R sgp130Fc Sequestration of sIL-6R [146]
NF-κB MMP (broad spectrum) Prinomastat Chelation of Zn(II) in the catalytic domain [147]
HIF-1 HIF-1 Amphotericin B Increased activity of FIH [148]
HIF-1 HIF-1 Echinomycin Inhibition of DNA binding [149]
HIF-1 HIF-1 α-Ketoglutarate Reactivation of PHD proteins [141]
HIF-1 HIF-1 Curcumin Oxidation and proteasomal degradation of HIF-1β [150]
HIF-1 HIF-1 Acriflavine Binding to HIF-1α dimerization domain [151]
ASK1 AP-1 Retinoic acid (and analogs) Inhibition of DNA binding (does not involve RARα) [152]
ASK1 JNK1 SP600125 Reversible ATP antagonist [153]
ASK1 p38α/β SB202190 Reversible ATP antagonist [154]
ASK1 p38α/β Sb203580 Reversible ATP antagonist [154]
ASK1 p38α/β PD169316 Reversible ATP antagonist [154]
UPR HSP90 Geldanamycin (17-AAG) ATP antagonist [155]
UPR HSP90 CNF2024/BIIB021 ATP antagonist [156]
UPR HSP90 NVP-AUY922 Complex formation with HSP70 [157]
UPR HSP90 SNX-5422 ATP antagonist [158]
UPR HSP90 STA-9090 ATP antagonist [159]
UPR HSP70 SubA Antagonist [160]
UPR HSP70 VRS-155008 ATP antagonist [161]
UPR HSF1 KRIBB11 Inhibition of transcriptional activity [127]
UPR Proteasome Bortezomib Antagonist of catalytic site [162]
UPR IRE1/ATF6 4-Phenylbutyric acid (and analogs) Unknown [163]
UPR PERK GSK-2656157 APP antagonist [164]
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antioxidant stress response is activated by oxidative stress
(Section 3.1.1) and culminates in the neutralization, modifica-
tion, and cellular export of oxidized/oxidizing compounds
and/or potentially hazardous products of oxidation reactions
(Section 3.1.2). Given the experimental evidence that NRF2 is
activated following PDT (Section 3.1.3) and that inhibition of
NRF2-upregulated processes potentiates the efficacy of PDT
(Section 3.1.4), NRF2 seems to be an important mediator of
tumor cell survival following PDT.
It is important to realize that the short-lived ROS produced
during PDT cannot be scavenged by antioxidants produced
downstream of the NRF2 signaling pathway since these are
produced long past the half-lives of these ROS, unless there is
constitutive overexpression of this pathway. Rather, NRF2
may act as an essential factor for PDT-surviving tumor cells
to restore the redox imbalance and promote prolonged surviv-
al in a post-PDT microenvironment. Moreover, since NRF2-
upregulated proteins HO-1, MDR1, and ABCG2 are often
upregulated inmany cancer types, NRF2 is likely constitutive-
ly active in tumor cells, potentially desensitizing these cells to
PDT and thereby playing an instrumental role in also neutral-
izing the first wave of ROS directly produced by PDT. There-
fore, NRF2 inhibition strategies aimed at preventing NRF2
activity prior and/or post-PDT may prove to be beneficial
for the enhancement of PDT efficacy as a result of impaired
tumor cell adaptation to oxidative stress.
3.2 The NF-κB pathway
The NF-κB transcription factor family is mainly involved in
the communication between tissue cells and the immune sys-
tem. Both intracellular and extracellular signals are translated
by NF-κB into transcriptomic responses that ultimately enable
tumor cells to attract and support immune cells. NF-κB plays a
role in apoptosis, inflammation, proliferation, and activation
of the HIF-1 response [168]. Therefore, the activation of this
pathway after PDT supports the survival of tumor cells by
preventing apoptosis and promoting angiogenesis [169].
However, PDT may also repress NF-κB activity through re-
dox modifications under severe oxidative stress as well as
tumor necrosis factor α (TNF-α) signaling, which is
one of the main transcriptional targets of NF-κB, that
is concurrently triggered after PDT [170]. As such,
NF-κB represents a complicated survival pathway that
may be both activated and repressed by PDT, depending
on the severity of the oxidative insult and the interac-
tion with additional signaling pathways.
The following sections will discuss the potential activation
and repression mechanisms of NF-κB (Section 3.2.1), its
downstream transcriptional effects after activation, and the
function of several of the upregulated proteins (Section 3.2.2).
After a brief summary of the available evidence for the partic-
ipation of NF-κB in the response of tumor cells to PDT
(Section 3.2.3), an outline of possible inhibition strategies
for NF-κB and its downstream gene products is provided
(Section 3.2.4).
3.2.1 Activation mechanisms of NF-κB
NF-κB comprises a family of proteins that include
reticuloendotheliosis (REL) A, RELB, and c-Rel, as well
as NF-κB1 and NF-κB2 [171, 172]. Two types of hetero-
dimeric complexes can be formed from these proteins,
each induced by different stimuli. NF-κB transcription fac-
tors composed of RELA, c-REL, and NF-κB1 are activat-
ed in the presence of proinflammatory cytokines and/or
hypoxia. NF-κB complexes composed of RELB and
NF-κB2 are induced solely by TNF-α. Both complexes
mediate the transcription of similar target genes that con-
tain κB elements in their promoter region and thus initiate
an inflammatory response to, e.g., ROS and TNF-α [172].
Under normal conditions, NF-κB transcription factors are
retained in the cytosol by inhibitors of κB (IκB) [168].
NF-κB is activated when IκB is phosphorylated by the
IκB kinase (IKK) complex at Ser32 and Ser36, which
results in the ubiquitination and degradation of IκB and
corollary release and nuclear translocation of NF-κB [172].
Accordingly, the IKK complex plays a major role in the
activation of NF-κB. The IKK complex is able to deacti-
vate the IκB protein in response to three independent fac-
tors, namely in response to ROS, hypoxia, and TNF-α
(Fig. 4).
NF-κB activation by ROS ROS is a primary activator of
NF-κB via oxidation of the IKK complex. IKK is composed
of two subunits with kinase activity, termed IKKα and IKKβ,
which are held together by one or two regulatory subunits
called IKKγ (or NF-κB essential modulator, NEMO) [172].
The exact mechanism underlying IKK activation by ROS is
relatively unclear and appears to be cell type-specific. In CME
and Jurkat T-lymphocytes, H2O2 treatment induced phosphor-
ylation of IκB via IKK, of which the activity was dependent
on SH2-containing inositol 5′-phosphatase 1 (SHIP-1) [173].
However, in various human cancer cell lines and ROS-
inducing treatments, the ROS-dependent phosphorylation of
IKK involves protein kinase D (PKD), sarcoma (SRC), and
Abelson murine leukemia viral oncogene (ABL) [174, 175],
c-SRC [176], MAPK kinase (MKK)3 [177] (downstream of
ASK1, Section 3.2.4), or NF-κB inducing kinase (NIK) [178].
Additionally, IKKγ contains two redox-sensitive cysteines
(Cys54 and Cys347) that may be instrumental in the formation
of IKKγ dimers in the presence of ROS, leading to enhanced
complex formation and IKKα/β phosphorylation [179]
(reviewed in [180]).
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NF-κB activation by hypoxiaA secondmechanism that may
contribute to NF-κB activation following PDT is hypoxia. The
hypoxic response leading to increased NF-κB activity is quite
similar to the activation of HIF-1 in that the inhibition of the
hydroxyl transferase activity of prolyl hydroxylase domain
proteins (PHD)1 and PHD3 and possibly, but less prominent-
ly, factor inhibiting HIF-1 (FIH) play a role in the activation of
IKK (reviewed in [181]). Although unequivocal experimen-
tal evidence is currently lacking, NF-κB activation by hyp-
oxia is most likely facilitated by the hydroxylation of IKK.
Similar hydroxylation-sensitive sites that were found on
HIF-1α have been identified on IKKα and IKKβ [182],
which interact with Von Hippel-Lindau (VHL) protein and
subsequently promote polyubiquitination and proteasomal
degradation [183]. Thus, it appears that PHD1 and PHD3
are able to hydroxylate and inactivate IKK complexes during
normoxia and that this inactivation capacity is lost during
hypoxia, potentially resulting in reduced proteasomal degra-
dation of IKK. It should be noted that reduced degradation of
the IKK complex may not be sufficient to confer NF-κB acti-
vation and that it has been proposed that hypoxia does not play
a major role in the activation of NF-κB [168]. However, hyp-
oxia may act in a costimulatory manner for the ROS-
(Section 3.2.1.1 NF-κB activation by ROS) or TNF-α-
mediated activation of NF-κB [181] (Section 3.2.1.3 NF-κB
activation by TNF-α).
NF-κB activation by TNF-α Thirdly, NF-κB can be induced
via paracrine/autocrine signaling by TNF-α from tumor cells and
chemoattracted immune cells. TNF-α is a downstream gene
Fig. 4 Potential activation mechanisms of NF-κB in response to PDT.
ROSmay activate IKK directly by oxidizing redox-sensitive cysteines on
IKKγ. Alternatively, IKKα/βmay be phosphorylated by kinases such as
PKD, ABL, SRC, NIK, and/or MKK3 in response to oxidative stress.
Hypoxia is likely a coactivator of the IKK complex, since depletion of
oxygen (O2→ROS) renders PHD1/3 and FIH dysfunctional, as a result
of which hydroxylation of IKKγ cannot occur and IKKγ is no longer
targe ted for proteasomal degradat ion by VHL-media ted
polyubiquitination. Finally, in the presence of TNF-α, the TNFR
becomes activated and triggers the assembly of a complex in which
TRADD, TRAF2/5, and cIAP1/2 promote the phosphorylation of
IKKα/β. A stabilized and activated IKK complex phosphorylates IκB,
which dissociates from the NF-κB complex and relieves its sequestration
in the cytoplasm. Upon release, NF-κB translocates to the nucleus to
induce a transcriptional response that promotes proliferation,
inflammation, angiogenesis, and survival. Via COX-2, EGFR signaling
activates of a variety of kinases (e.g., PKD,MKK3, ABL, SRC, NIK) that
in turn phosphorylate and activate the IKK complex. Active NF-κB
transcription factors induce the transcription of genes involved in
proliferation, inflammation, angiogenesis, and survival. The underlined
genes have been extensively investigated in relation to PDT and are
discussed in detail in the main text. CCND1 encodes cyclin D1, PTGS2
encodes COX-2, and BIRC5 encodes survivin
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target of both AP-1 and NF-κB and thus provides a positive
feedback loop for NF-κB activation as well as activation of the
ASK1 pathway (Section 3.4). TNF-α binds the TNF receptor
(TNFR) that subsequently forms activated homodimers. A sig-
naling complex is formed by the recruitment of TNFR associated
with death domain (TRADD), TRAF2/5, and cytosolic inhibitor
of apoptosis (cIAP)1/2. The complex associates with a linear
ubiquitin assembly complex that polyubiquitinates RIP1 and
IKKγ, forming an active IKK complex. The active IKK complex
is further activated by ubiquitinated RIP1, which in turn leads to
the activation of TGF-β-activated kinase 1 (TAK1) and conse-
quent phosphorylation of IKKα and IKKβ. The activated IKK
complex also phosphorylates and inactivates IκB, triggering the
release and nuclear translocation of the NF-κB transcription fac-
tor complex (reviewed in [184]).
NF-κB inhibition by ROS and TNF-α during severe oxi-
dative stress In contrast to the activatory capacity of ROS and
TNF-α described above, severe forms of oxidative stress and/
or the combination of oxidative stress and TNF-α signaling
inhibit the activity of NF-κB and promote cell death. Whereas
minor or moderate levels of oxidative stress lead to NF-κB
activation (Section 3.2.1.1 NF-κB activation by ROS), severe
oxidative stress has a detrimental effect on NF-κB activity
[185]. Critical cysteines in NF-κB complexes, such as
Cys62 on RELA, are susceptible to oxidation and subsequent
glutathionylation or nitrosylation, which impairs DNA bind-
ing and transcriptional activity [186, 187]. Additionally,
IKKα and IKKβ contain redox-sensitive Cys179, which can
be oxidized by H2O2 and reduce IKK kinase activity [188].
These findings suggest that antioxidants produced de novo via
e.g., the NRF2 pathway may facilitate NF-κB activation fol-
lowing a severe prooxidative insult such as PDT by amelio-
rating the oxidative stress, although more research is required
to corroborate this claim. TNF-α exerts its anti-NF-κB effects
primarily via mitochondrial ROS production, which may ele-
vate the extent of preexisting moderate oxidative stress to
severe oxidative stress and consequent NF-κB inhibition via
the abovementioned processes. For example, TNF-α treat-
ment was shown to cause oxidative stress, the cytotoxicity
of which could be repressed by the addition of antioxidants
[189]. Inhibition of NF-κB by TNF-α-induced oxidative
stress stimulates cell death via prolonged activation of
JNK1, given that NF-κB target gene products such as A20
and growth arrested and DNA damage (GADD)45β typically
inhibit JNK1 activity. As such, ROS have been considered to
act as a secondary messenger in TNF-α-induced cell death
(reviewed in [185]).
The ROS-dependent activation of the NF-κB pathway has
several important biological and clinical implications for PDT.
Laser irradiation of tissue is characterized by light intensity
attenuation with increasing depth as a result of light scattering
and absorption [190], resulting in fluence gradients during
PDT. Inasmuch as the extent of ROS production is proportional
to the fluence [78], the cancer cells in the more distally located
regions of the tumor may exhibit less ROS generation during
PDTand hence are subject to a lower degree of oxidative stress
than the tumor cells most proximal to the light source. Accord-
ingly, irradiation of bulky tumors may yield a fraction of cancer
cells that undergoes cell death without the activation of ROS-
triggered survival pathways, whereas another fraction of cancer
cells, located mainly at the deep periphery of the target tissue,
may suffer from oxidative stress but survive as a result of ROS-
mediated activation of e.g., NF-κB-mediated survival path-
ways. The latter fraction of cancer cells is particularly important
therapeutically inasmuch as these cells may cause tumor re-
growth and metastasis after PDT.
3.2.2 Downstream effects of the NF-κB pathway
The different NF-κB transcription factor complexes essential-
ly share the same target genes that are associated with cell
proliferation, inflammation, angiogenesis, and survival [172]
(Fig. 4). NF-κB transcription factors induce cell proliferation
(upregulation of cyclin D1 (encoded by CCND1) and VEGF);
cause inflammatory cells to be recruited toward the tumor site
(via the production and secretion of interleukin (IL)-1α/β, IL-
2, IL-6, IL-8 (CXCL8), granulocyte-macrophage colony stim-
ulating factor (GM-CSF, CSF2), TNF-α, cluster of differenti-
ation 40 ligand (CD40LG), chemokine C-X-C motif ligand
(CXCL) 2, and cyclooxygenase 2 (COX-2, encoded by pros-
taglandin synthase 2 (PTGS2)); trigger angiogenesis by up-
regulation of matrix metalloproteinases (MMPs), VEGF, and
PTGS2; and facilitate inflammatory cell binding via selectin E
(SELE), intercellular adhesion molecule (ICAMs), and vascu-
lar cell adhesionmolecule (VCAMs) [168, 172, 191–193]. The
role of NF-κB target gene products ICAM and VCAM ap-
pears to be controversial insofar as PDT reduced gene and
protein expression levels despite activation of NF-κB [194,
195]. Of the inflammation-associated proteins, IL-6 plays an
important role in tumor cell survival following PDT, as
discussed in Section 3.2.2.4 IL-6, whereas TNF-α is also di-
rectly responsible for inducing cell death via apoptosis and
necrosis pathways, as discussed in Section 3.2.2.3 TNF-α.
To ensure survival of immune cells in a hypoxic environment,
NF-κB desensitizes cells to apoptosis through the upregula-
tion of cIAP1 (baculoviral inhibitor of apoptosis repeat-
containing 2, BIRC2), cIAP2 (BIRC3), and survivin (BIRC5)
as well as CFLAR, COX-2, and antiapoptotic members of the
BCL2 family (BCL2A1, BCL2L1) [192, 196]. Especially
survivin and COX-2 have been implicated in cell survival
following PDT (Sections 3.2.2.1 COX-2 and 3.2.2.2
Survivin). In addition to these antiapoptotic proteins,
NF-κB triggers HIF1A transcription that promotes im-
mune and tumor cell survival in a hypoxic environment
as a result of the upregulated production of HIF-
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1 transcription factor [197] (Section 3.3). NF-κB further
initiates a negative feedback loop toward its own activ-
ity by inducing the expression of IκB subunits and the
NF-κB inhibitor A20 [172, 198].
Overall, NF-κB stimulates tumor cell survival by inhibiting
apoptosis and recruiting the immune system to facilitate an-
giogenesis and promote cell proliferation. The induction of
NF-κB and the consequent production of cytokines may also
be essential to the antitumor immune response (Section 2.2.3),
which is essential for complete tumor eradication [76, 77] and
long-term deterrence of tumor regrowth [199].
COX-2 COX-2 (encoded by PTGS2) is overexpressed in
many types of cancer and is generally associated with reduced
patient survival [200]. The promoter sequence of COX-2 con-
tains binding sites for NF-κB, HIF-1, ATF2, FBJ murine os-
teosarcoma viral oncogene homologue (FOS), and JUN
[201–203], making it a downstream target of three major sur-
vival pathways that are induced by PDT. The main function of
COX-2 is to convert arachidonic acid to prostaglandin H2
(PGH2), which is further metabolized into PGE2, PGF2α,
PGI2, and thromboxane A2 (TBA2) [204]. PGE2 induces
growth of tumor epithelial cells by binding the PGE2 receptor
and activating rat sarcoma protein (RAS) and phosphatidyl
inositol 3 kinase (PI3K), which activate signaling pathways
that ultimately lead to proliferation and cell division
[205–207]. In addition, prostaglandins induce SRC, epidermal
growth factor receptor (EGFR), MMP2, and C-C chemokine
receptor 7 (CCR7) to stimulate cell migration [208–210].
Prostaglandins also stimulate angiogenesis by facilitating the
production of VEGF, fibroblast growth factor (FGF)2, and
molecules involved in immune cell chemotaxis and adhesion,
including chemokine C-X-C motif ligand (CXCL)1, integrin
αVβ3, chemokine C-Cmotif ligand (CCL)2, and CXC recep-
tor 4 [207, 211–213].
Survivin Survivin is a member of the inhibitor of apoptosis
protein (IAP) family, which also comprises NLR family
apoptosis-inhibitory protein, cIAP1, cIAP2, X-linked IAP
(XIAP), and livin [214]. The expression of the genes that
encode these proteins (BIRC1-4 and BIRC7) is generally in-
duced by transcription factor 4, signal transducer and activator
of transcription 3 (STAT3), as well as the PDT-induced tran-
scription factors NF-κB and HIF-1 (reviewed in [215]).
Survivin is considered a nodule protein; a protein that stands
at the center of many signaling pathways and plays a role in
many cellular processes. In general, survivin stimulates cell
division in the mitotic phase of the cell cycle and suppresses
apoptosis (reviewed in [145]). Survivin also partakes in a
chromosomal passenger complex that binds kinetochores
and stimulates spindle formation to facilitate chromosome
segregation during mitosis. The antiapoptotic role of survivin
is reflected by its inhibition of caspase 9 [216] and prevention
of XIAP degradation [145, 217]. Furthermore, alternatively
spliced variants of survivin have been reported to interact with
BCL2 and inhibit caspase 3 and BCL2-associated X protein
(BAX) activity [218]. These proliferative and cytoprotective
capacities of survivin make it a strong inducer of tumor cell
survival in a post-PDT environment.
TNF-α In addition to activating the NF-κB response that
stimulates survival, TNF-α is known as a potent trigger of
apoptosis via the extrinsic pathway as well as necrosis via
programmed necrosis or necroptosis. When it binds TNF-α,
TNFR1 homodimerizes and recruits TRADD and TRAFs to
its cytoplasmic domain. In turn, TRADD activates FAS-
associated with death domain (FADD) and RIP1, which
cleaves procaspase 8 to its active form. Subsequently, caspase
8 cleaves BH3 interacting domain death agonist (BID), yield-
ing truncated BID (tBID) that forms a pore in the mitochon-
drial membrane and allows cytochrome c leakage. Cyto-
chrome c leakage results in its binding to apoptotic protease
activating factor 1 (APAF-1); activation of caspases 9, 3, and
7; and the subsequent activation of the caspase cascade and
corollary execution of apoptosis (reviewed in [184]).
Programmed necrosis is the result of RIP1 activation (by
e.g., TNF-α), which forms an autophosphorylating complex
with RIP3. This complex activates mixed lineage kinase
domain-like protein that interacts with members of the phos-
phoglycerate mutase family, culminating in the dephosphory-
lation of dynamin-related protein 1 and the execution of ne-
crosis [184, 219]. The inhibitor of apoptosis proteins (IAPs)
constitute the inhibitors of these cell death pathways, which
are also upregulated by the NF-κB-TNF-α signaling loop
(Section 3.4.2). IAPs have a plethora of functions, and only
a brief summary of the most relevant functions is given here.
cIAP1/2 act as ubiquitin ligases for RIP1, thereby inhibiting
the apoptotic and necroptotic pathways orchestrated by
TNF-α while also stimulating RIP1-mediated IKK activation
(reviewed in [220]). Additionally, cIAP1/2 is capable of
inhibiting the functions of caspases 3, 7, and 9 and therefore
of preventing the execution of apoptosis (reviewed in [221]).
cIAP1/2 also inhibits TNF-α signaling by polyubiquitination
of NIK and activates JNK and p38MAPK [222, 223] to regulate
survival, apoptosis, inflammation, and proliferation, which is
covered in greater detail in the context of the ASK1 survival
pathway (Section 3.4). As stated previously (Section 3.2.2.2
Survivin), survivin is also an IAP family member that inhibits
apoptosis and regulates mitosis (reviewed in [145]).
IL-6 One of the most abundant cytokines released by PDT-
treated tumor cells is IL-6, which is upregulated by NF-κB
and AP-1 transcription factors [224]. IL-6 functions as a pro-
inflammatory cytokine that binds to the IL-6 receptor (IL-6R)
expressed predominantly by immune cells and hepatocytes, or
to soluble IL-6R (sIL-6R), which is formed via alternative
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splicing of IL-6R mRNA. The IL-6-IL6R and IL-6/sIL-6R
complexes can heterodimerize with glycoprotein 130
(gp130) that is ubiquitously expressed by most cell types,
including tumor cells [225]. Stimulated gp130 autophospho-
rylates its intracellular tyrosine kinase domain [225], leading
to activation of Janus kinase proteins and the phosphorylation
and subsequent nuclear translocation of STAT3 [226]. More-
over, IL-6 triggers proliferation by activating the RAS-MAPK
and PI3K-protein kinase B pathways, resulting in the expres-
sion of WNT and COX-2 [226]. Via these pathways, IL-6
trans-signaling induces the epithelial-mesenchymal transition
of tumor cells that promotes invasion, metastasis, and disease
progression [227–229]. STAT3 is regarded as the main effec-
tor of IL-6 signaling and plays an important role in the surviv-
al and proliferation of tumor cells and immune cells [230].
Moreover, STAT3 enhances angiogenic signaling and regu-
lates the production of chemoattractants for neutrophils and
macrophages [231]. Upon dimerization, STAT3 binds to in-
terferon (IFN)γ-activated sequence elements to promote sur-
vival by upregulating BCL2L1, myeloid leukemia cell differ-
entiation protein (MCL1), BIRC4, and BIRC5 (survivin) while
downregulating TP53 [231]. Survival is additionally stimulat-
ed through upregulation of HSP70, regenerating islet-derived
protein IIIβ and γ, trefoil factor 3, as well as the antioxidant
enzymes Mn-SOD, ferritin, and catalase (reviewed in [231]).
Proliferation is induced via STAT3 by upregulation of c-JUN,
c-FOS, c-MYC, as well as cyclins D and B that mediate cell
cycle progression through the G1/S and S/G2 phases, respec-
tively. STAT3 also promotes angiogenesis by facilitating the
production of VEGF, HIF-1α, and basic FGF. Besides its role
in tumor (re)growth, STAT3 also prompts the immune system
by assisting in the production of a wide array of proinflamma-
tory cytokines and chemokines that includes, but is not limited
to, CCL2, CXCL2, IL-1β, IL-1α, TNF-α, and IFNγ (the role
of STAT3 in conjunction with NF-κB is comprehensively
reviewed in [231]).
Matrix metalloproteinases Remodeling of the tumor micro-
environment is essential for cancer progression, and NF-κB
stimulates the expression of enzymes that facilitate extracellu-
lar matrix remodeling. MMPs are a family of proteins that
cleave matrix peptides to facilitate extracellular matrix remod-
eling, cell migration, and angiogenesis [232]. These proteins
are abundantly expressed by tumor cells, tumor-associated
fibroblasts, endothelial cells, and tumor-infiltrated immune
cells [233]. MMPs also act as signaling molecules that inhibit
apoptosis [232]. By contrast, MMPs have been associated
with reduced angiogenesis due to the generation of the
antiangiogenic compounds angiostatin and endostatin during
the degradation of plasminogen (MMPs 2, 3, 7, 9, and 12) and
collagen XVIII (MMPs 3, 9, 12, 13, and 20), respectively
[234]. The exact role of MMPs in tumor biology and
responsiveness to PDT is currently elusive and deserves fur-
ther context-dependent investigation.
3.2.3 Role of the NF-κB pathway in PDT
NF-κB is one of the major transcription factors induced by
PDT [194, 195, 235–239], although in some instances NF-κB
was also found to be downregulated following PDT, such as in
nasopharyngeal carcinoma (hypericin as photosensitizer) and
breast cancer cell lines (C-phycocyanin as photosensitizer)
[240, 241]. Despite the elusive NF-κB activation mecha-
nism(s) in case of PDT, it is clear that NF-κB activation does
occur after PDT on the basis of findings concerning at least
two downstream targets of the NF-κB transcription factor,
namely COX-2 and survivin. COX-2 mRNA and protein
levels as well as COX-2 activity were increased after PDT in
a multitude of studies [202, 239, 242–246], albeit COX-2
activity was not necessarily attributed to NF-κB activation
[247] but rather to IL-6 or p38MAPK signaling [243, 244,
248]. Similarly, survivin (Section 3.2.2.2 Survivin) was up-
regulated and phosphorylated after PDT in a number of stud-
ies [249–253]. This upregulation was most likely mediated by
E2F and STAT3 transcription factors [254], which are indi-
rectly activated by PDT through growth factors (e.g., epider-
mal growth factor (upregulated via the ASK1-AP-1 pathway,
Section 3.4.2.2 Prolonged downstream effects of ASK1 acti-
vation) and VEGF) and cytokines (IL-6) downstream of the
HIF-1 and NF-κB pathways (Section 3.2.2). IL-6 functions as
a survival factor and also as a regulator of the antitumor im-
mune response after PDT by activating STAT3 and COX-2.
Presently, it is unclear whether inhibition of IL-6 signaling by
for example blocking AP-1 and/or NF-κB is beneficial or
detrimental to tumor response. Several studies have explored
the function of IL-6 following PDT, but the investigations
have yielded contradictory results. First, expression levels of
IL-6 vary depending on the cell line, at least in case of naso-
pharyngeal cancer cell lines. Whereas CNE-2 cells showed a
13-fold increase in IL-6 mRNA levels compared to untreated
cells, HK-1 cells exhibited only a 1.4-fold increase in IL-6
mRNA levels 6 h post-PDT. The effect of IL-6 overexpression
on the response to PDTwas not investigated [255]. Secondly,
the outcomes regarding the prosurvival or prodeath role of IL-
6 are conflicting. On the one hand, IL-6 stimulated tumor cell
survival and negatively regulated the antitumor immune re-
sponse in mice bearing Colo26 xenografts [256]. Similarly,
IL-6 induction by PDTwas associated with cell death inhibi-
tion and enhanced tumor growth in human basal cell carcino-
ma (BCC-1/KMC) cells [247] and mice bearing subdermal
Co26 murine colon carcinomas or 4T1 mammary carcinomas
[256]. On the other hand, a beneficial effect of IL-6 overex-
pression for PDT has been reported. Tumor growth in mice
was reduced by IL-6 in human prostate cancer (LnCAP) xe-
nografts [257] and human neuroblastoma (WAC2) xenografts
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[258]. Similarly,mice bearing Lewis lung carcinomasweremore
susceptible to PDTwhen the cells overexpressed IL-6 [259]. In a
clinical setting, high levels of IL-6 following PDT of
cholangiocarcinomas correlated positively with increased tumor
mass, indicating that elevated IL-6 levels enhance tumor growth
and/or recurrence following PDT [260]. With respect to tran-
scriptional regulation ofMMPs after PDT, the AP-1 transcription
factors FOS and ATF2 that are activated in the ASK1 survival
pathways (Section 3.4.2.1 Acute downstreameffects of ASK1
activation) aswell asNF-κBare able to upregulate the expression
of MMP1, MMP2, MMP3 [261, 262], and MMP9 [263]. How-
ever, the regulation of MMPs following PDT is ambivalent. For
example, MMPs 1–3 were upregulated or activated in HK-1
nasopharyngeal carcinoma cells, MCF-7 mammary carcinoma
cells and xenografts, in a Walker carcinosarcoma model, and in
keratinocyte-associated fibroblasts that were subjected to PDT
[240, 264–266]. Furthermore, long-term upregulation of
MMP9 but not MMP1, MMP3, MMP7, and MMP12 was ob-
served in actinic keratosis patients treated by PDT [267]. Con-
versely, several studies have reported the downregulation of
MMPs after PDT, including MMP2 and MMP9 in human naso-
pharyngeal carcinoma, oral cancer, medulloblastoma, and glioma
cell lines (HK-1; UP and VB6; MED TE-671; and U87 and
GBM6840 cells, respectively) [240, 268–270]. The reduction
in MMP2 and MMP9 levels was associated with retarded tumor
cell migration [268, 269]. Furthermore, human glioma spheroids
treated with PDTexhibited reduced MMP7 and MMP8 levels, a
depolarized morphology, and a reduced migration and invasion
capacity compared to untreated spheroids [271].
3.2.4 Inhibition strategies for NF-κB and its downstream
targets
Inhibition of NF-κB Terpenoids are NF-κB inhibitors with a
variety of structures and various modes of action [272] (Table 1).
The sesquiterpene parthenolide has proven particularly useful for
promoting the alkylation of Cys38 in the RelA subunit of
NF-κB, thereby preventing DNA binding [137, 272]. Alterna-
tively, panepoxydone is an inhibitor of NF-κB that blocks phos-
phorylation of IκB by TNF-α without coincident activation of
AP-1 in COS-7 monkey kidney cells [138]. However, neither
parthenolide nor panepoxydone has been employed in studies
combined with PDT. The small molecule Bay 11-7082 is fre-
quently used as a chemical inhibitor of IKK to prevent NF-κB
activation both in vitro and in vivo. This compound effectively
inhibited TNF-α-mediated phosphorylation and activation of
IKK in lipopolysaccharide-treated murine RAW264.7 macro-
phages, which translated to impaired phosphorylation and cyto-
solic retention of NF-κB [139]. However, as shown by Lee et al.,
themain target of Bay 11-7082 does not appear to be IKK since it
also inhibits AKTphosphorylation upstream of IKK activation in
the TNF-α signaling pathway [139]. The activity of c-FOS and
c-JUN was also diminished by Bay 11-7082 in COS-7 cells
[139]. Thus, the inhibitory mechanism of Bay 11-7082 on
NF-κB stems from its action at sites upstream of IKK rather than
direct modulation of NF-κB activity (Table 1).
The precise mechanism notwithstanding, Coupienne et al.
demonstrated that LN18 human glioblastoma cells were sig-
nificantly more sensitive to ALA-PDT following incubation
with 10 μM of Bay 11-7082 for 30 min prior to PDT [273].
Contrastingly, we have recently demonstrated that siRNA-me-
diated inhibition of the RelA subunit of NF-κB resulted in
reduced susceptibility of murine mammary carcinoma
(EMT-6) cells to ZnPC-PDT. While cell viability post-PDT
increased in RelA-inhibited cells, the PDT-treated cells re-
leased increased levels of TNF-α, CCL2, and IL-6. Accord-
ingly, the supernatant isolated from these cells exerted en-
hanced immunogenicity on RAW264.7 murine macrophages
[274]. In agreement with these results, Chen et al. found that
Bay 11-7082 and also SP600125, an inhibitor of JNK
(Table 1), greatly reduced the amount of apoptotic human
Ca9-22 oral cancer cells following ALA-PDT, suggesting that
NF-κB and JNK jointly regulate apoptotic signaling following
PDT [275]. However, given the multitude of inhibitory effects
of Bay 11-7082, it is difficult to ascertain whether the in-
creased or reduced sensitization to PDT is the result of
NF-κB inhibition or of impaired AP-1 activity. Rapozzi et al.
reported that pheophorbide A-PDT in combination with the
NF-κB inhibitor dehydroxymethylepoxyquinomicin
(DHMEQ, Table 1) [140] promoted cell death in B78-H1
murine amelanotic melanoma cells compared to PDTwithout
DHMEQ [276], which is in support of PDT-induced NF-κB-
mediated survival signaling.
Since NF-κB and HIF-1 share a similar activation mecha-
nism following PDT (Sections 3.2.2 and 3.3.2), α-
ketoglutarate may serve as an inhibitor of both signaling cas-
cades (Table 1). PHD1 and 3 lose their HIF-1 and NF-κB
inhibitory capacity under hypoxic conditions, but the activity
of PHDs can be restored by increasing intracellular α-
ketoglutarate levels, even under low oxygen tensions [277].
Moreover, the activation pathways of NF-κB and HIF-1 are
highly interconnected due to transcriptional upregulation of
HIF-1α mRNA by NF-κB and also the HIF-1-mediated pro-
duction of cytokines, such as TNF-α, that can activate NF-κB.
Since hypoxia does not play a major role in the activation of
NF-κB [168], NF-κB activation is more likely to result from
TNF-α production downstream of the HIF-1 and AP-1 path-
ways. However, studies in our lab with liposomal zinc
phthalocyanine-PDT have shown that incubation of tumor
cells with free or liposome-delivered α-ketoglutarate does
not enhance PDT efficacy (Broekgaarden, M. et al., Nano
Research, in resubmission; Weijer, R. et al., Oncotarget, in
resubmission), which is further discussed in Section 3.3.4.
Inhibition of COX-2 COX-2 is an important regulator of
post-PDT survival [278] insofar as inhibition of COX-2 prior
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or during PDT has consistently yielded increased tumor cell
death after PDT [242, 244, 245, 251, 279–281]. Since COX-2
is under the control of both NF-κB and ATF2, inhibition of
NF-κB (with, e.g., Bay 11-7085) and also p38α (with, e.g.,
PD169316, SB202190, or SB203580, Table 1) indeed re-
duced COX-2 protein levels and increased the responsiveness
to PDT in human ovarian (HeLa) and bladder cancer (T24)
cells as well as radiation-induced mouse fibrosarcoma (RIF-1)
cells [202, 239, 244]. In addition, suppression of the AP-1
activators protein kinase C (PKC) and MKK1 and 2 led to
decreased COX-2 levels in hypericin-PDT-treated T24 cells
and porfimer sodium-PDT-treated RIF-1 cells [202, 239].
These results further attest to the importance of the AP-1
and NF-κB signaling pathways in terms of COX-2 activation
and the survival response that ensues after PDT. The most
commonly used COX inhibitors are nonsteroidal anti-
inflammatory drugs (NSAIDs), which bind to Arg120 of
COX-1 and COX-2 to subsequently block the conversion of
arachidonic acid to PGH2 [142, 282, 283] (Table 1). Some
NSAIDs bind only to COX-1 (e.g., flurbiprofen), whereas
others bind to both COX-1 and COX-2 (e.g., naproxen, indo-
methacin, ibuprofen, and aspirin) [284] or inhibit COX-2 di-
rectly, including celecoxib, rofecoxib, nimesulide, diclofenac,
meloxicam, and the related compound NS-398 [142, 284,
285]. The latter two groups of inhibitors are suitable for use
in PDT because they target COX-2. Accordingly, inhibition of
COX-2 prior or during PDT with NSAIDs decreased tumor
cell survival in a variety of (tumor) cell lines [242, 245, 251,
279–281, 286], which coincided with a reduction in levels of
PGE2 [244, 280] and the proangiogenic factors MMP9,
TNF-α, IL-1β, IL-10, and VEGF [280]. Moreover, inhibition
of COX-2 with NSAIDs caused a reduction in the levels of the
antiapoptotic protein survivin [251].
One of the concerns of inhibiting COX-2 activity is that the
consequent reduction in cytokine production may abolish the
antitumor immune response necessary for long-term protec-
tion against tumor recurrence [169] and removal of residual or
non-PDT damaged tumor cells in immunocompetent hosts
[83, 84]. However, blocking of COX-2 with celecoxib, NS-
398, or nimesulide showed considerably increased survival of
immunodeficient mice in which various tumor cell lines were
xenografted [242, 245, 251, 280]. Thus, the inhibition of
COX-2 activity with NSAIDs could be a valuable intervention
strategy for PDT to reduce tumor cell survival and potentially
reduce the proangiogenic effects induced by PGE2.
Inhibition of survivin Inhibition of survivin, which is upreg-
u la t ed by ac t iva t ion o f NF-κB fo l lowing PDT
(Section 3.2.2.2 Survivin), may reduce antiapoptotic signaling
and therefore could result in increased PDT efficacy. Several
different compounds that inhibit survivin are available that
either block upstream activators such as HSP90 (17-AAG)
and STAT3 (STA-21 [143] or WP1066 [144]) or inhibit
survivin directly via antisense RNA interference
(LY218130B) and/or transcriptional repression (YM155 and
EM1421) [145] (Table 1), although the specificity of the latter
compounds may not be restricted to survivin [287].
Some investigations studying the inhibition of survivin
during PDT have employed geldanamycin (17-AAG) to in-
hibit HSP90-induced survivin expression [250, 252],
celecoxib or 2,5-dimethyl celecoxib [251] for direct inhibition
of survivin (although the mechanism by which these com-
pounds inhibit survivin remains elusive), or have applied gene
knockdown strategies [249]. Regardless of the inhibition strat-
egy, all these studies point toward an increased tumoricidal
effect of survivin inhibition during PDT, making survivin an
important target for PDT enhancement strategies.
Inhibition of IL-6 Unequivocal evidence for the prosurvival
role of IL-6 in PDT-subjected tumor cells is lacking since both
beneficial and detrimental effects of IL-6 signaling in terms of
cell survival have been observed after PDT (Section 3.2.2.4
IL-6). Although the use of IL-6 inhibitors has not been ex-
plored in PDT research, cancer-related studies in which IL-6
signaling was inhibited may provide clues as to the potential
(neo)adjuvant efficacy of IL-6 inhibitors for the enhancement
of PDT. A specific blocker of IL-6/sIL-6R transactivation has
been developed by fusing the extracellular domain of human
gp130 to a human IgG1 antibody (sgp130Fc, Table 1). The
molecule was shown to effectively block IL-6 signaling in
mouse and rat models of autoimmune disease (reviewed in
[146] and [288]). For example, sgp130Fc significantly
prevented disease progression in inflammation-associated
mouse cancer models. Thus, blocking of IL-6 transactivation
with sgp130Fc after PDT could increase the therapeutic po-
tential and may be instrumental in elucidating the role of the
IL-6 signaling pathway in tumor cell survival.
Inhibition of matrix metalloproteinases Inhibitors for
MMPs are readily available, and most agents inhibit mul-
tiple MMP isoforms. This is particularly important since
the antitumor effects of MMP inhibitors are not confined
to a single isozyme but are mediated by, e.g., MMP3,
MMP8, and MMP12 [232]. Ferrario et al. investigated
the broad spectrum MMP inhibitor prinomastat [147]
(Table 1) in combination with PDT in mouse BA mam-
mary carcinoma xenografts [289] after observing in-
creased levels of MMP2 and MMP9 expression after
porfimer sodium-PDT. Long-term cures were found in
46 % of mice treated with prinomastat and PDT versus
only 20 % in mice treated with PDT alone, although the
enzymatic activity in the presence of prinomastat was not
assayed. Accordingly, the inhibition of MMPs during
PDT holds potential for the enhancement of therapeutic
efficacy. Despite the positive results, caution should be
exercised when designing an MMP inhibitor-based
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combinatorial treatment in light of the variable regulation
of different MMP isozymes and their ambivalent biologi-
cal effects (tumor suppressing and tumor promoting). For
example, wound healing relies on MMPs, and it is possi-
ble that pharmacological inhibition may interfere with the
recovery of PDT-treated tissues.
3.2.5 Concluding remarks
The contribution of NF-κB to the cell survival response appears
to be well-established based on the studies that have demon-
strated NF-κB activation following PDT (Section 3.2.3). At
least three possible mechanisms are responsible for NF-κB ac-
tivation after PDT (Section 3.2.1) and pharmacological inter-
ventions in the NF-κB survival pathway are possible to im-
prove PDT outcomes (Section 3.2.4). However, such interven-
tions may present a therapeutic quagmire. On the one hand, the
downstream targets of NF-κB are instrumental for tumor cell
survival following PDT, such as COX-2 and survivin, of which
the inhibition results in increased tumor cell death and better
tumor control (sections 3.2.4.2 Inhibition of COX-2 and 3.2.4.3
Inhibition of survivin). On the other hand, many proinflamma-
tory cytokines are upregulated byNF-κB that can attract cells of
the innate and adaptive immune system tomediate an antitumor
immune response. Interfering with the capability of the treated
cancer cells to produce a variety of cytokines and chemokines
may therefore inhibit the antitumor immune response and re-
duce long-term therapeutic efficacy. In contrast to the postula-
tions, it was recently shown that inhibition of NF-κB resulted in
increased cytokine release and immunogenicity of PDT-treated
tumor cells in vitro [274] and suggested that NF-κBmay not be
a suitable target for pharmacological inhibition in conjunction
with PDT. These contrasting results demonstrate that further
research on the in vitro and in vitro consequences is pivotal to
understand the complex functions of NF-κB in a post-PDT
tumor microenvironment.
3.3 The HIF-1 pathway
Tumor growth frequently leads to hypoxia since the tumor tissue
tends to outgrow its immature blood supply, as a result ofwhich a
hypoxia-induced inflammatory response is triggered to stimulate
angiogenesis and increase metastasis. Tumor cells cope with
mildly hypoxic conditions by constitutively activating HIF-1,
leading to the transcription of genes involved in anaerobic me-
tabolism, inflammation, and antioxidant responses [290]. Under
conditions of acute severe hypoxia or anoxia, tumor cells
hyperactivate HIF-1 and its downstream responses for purposes
of survival (Broekgaarden, M. et al., Nano Research, in resub-
mission; Weijer, R. et al., Oncotarget, in resubmission). HIF-1
activation has been observed in many PDT studies, and HIF-1
has been accepted as one of themainmolecular effectors induced
by PDT [246, 250, 291–294]. The remainder of this section will
address the four main activation mechanisms of HIF-1 (Sec-
tion 3.3.1) and the most important downstream effects that may
play a role in tumor cell survival post-PDT (Section 3.3.2). Ev-
idence for its activation after PDT is addressed in Section 3.3.3,
and the potential HIF-1 intervention strategies to enhance PDT
efficacy are discussed in Section 3.3.4.
3.3.1 Activation mechanisms of HIF-1
The HIF-1 transcription factor is a basic helix-loop-helix
(bHLH) heterodimeric protein composed of an α subunit
(HIF-1α or HIF-2α) and a β subunit (HIF-1β) subunit
[295]. HIF-1α is constantly transcribed but retained in the
cytosol and rapidly degraded under normophysiological con-
ditions. HIF-1β is constitutively expressed in the nucleus,
where it is separated from its dimerization partner HIF-1α in
the cytosol and thus kept inactive. Upon stabilization, HIF-1α
translocates to the nucleus, dimerizes with HIF-1β, and binds
DNA at hypoxia responsive elements (HREs) to initiate target
gene expression [296, 297]. The effects of HIF-1 activation
are profound, since over 500 genes are known to be a direct
target of HIF-1. Moreover, HIF-1 is involved in chromatin
remodeling complexes and microRNA expression that regu-
late gene expression at an epigenetic level [298–301]. There
are at least four different mechanisms by which HIF-1α may
become activated after PDT, namely hypoxia, ROS, NF-κB,
and COX-2. The pathways are summarized in Fig. 5.
HIF-1 activation by hypoxia HIF-1α acts as an oxygen sen-
sor in that it is constantly targeted for proteasomal degradation
under normoxic conditions as a result of hydroxylation and
subsequent polyubiquitination [295, 297, 302–305]. Hydrox-
ylation of HIF-1α by PHD2/3 and FIH leads to HIF-1α rec-
ognition and binding by VHL proteins, which act as a scaffold
for E3 ubiquitin ligase that polyubiquitinates HIF-1α as a
signal for proteasomal degradation [306, 307]. During hypox-
ia, which occurs after PDT (Section 2.2.2), HIF-1α hydroxyl-
ation by PHDs and FIH ceases because the hydroxylation
reaction requires O2 [308]. This causes HIF-1α to become
stabilized, move to the nucleus, complex with HIF-1β, and
activate gene transcription through HREs.
HIF-1 activation by ROS HIF-1α stabilization by hypoxia-
mediated PHD and FIH inactivation can also proceed through
ROS-mediated deactivation of PHDs and FIH in a manner that
is not necessarily dependent on intracellular oxygen tension
[309–311]. PHDs and FIH require Fe2+ as cofactor in their
conversion of α-ketoglutarate, O2, and proline to succinate,
CO2, and hydroxyproline, respectively. It should be noted that
succinate is an important electron donor in the citric acid cycle
[312]. Oxygen radicals, which are abundantly produced dur-
ing PDT (Section 2.2.1), are able to oxidize Fe2+ to Fe3+,
thereby inhibiting the enzymatic activity of PHDs and FIH
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and reducing hydroxylation-mediated degradation of HIF-1α,
even under normoxic conditions [313]. The ROS-driven acti-
vation of HIF-1 may also be significant under hypoxic condi-
tions. Hypoxia induces mitochondrial ROS release that was
shown to be responsible for an initial burst of HIF-1 activa-
tion, whereas hypoxia-driven, NADPH-oxidase-induced ROS
induced a second burst of HIF-1 activation in humanHS29-4T
melanoma cells [314]. Thus, the activation mechanisms of
HIF-1 by ROS and hypoxia appear to be interrelated.
HIF-1 activation by NF-κB In addition to modulation by
ROS and hypoxia, HIF-1α expression is at least partially un-
der the control of NF-κB since the promoter of the HIF1A
gene contains an NF-κB binding site [197]. Cultured pulmo-
nary artery smooth muscle cells incubated with H2O2 under
normoxic conditions exhibited NF-κB activation that was re-
sponsible for transcriptional upregulation of HIF-1α and the
HIF-1 target gene plasminogen activator inhibitor 1 (PAI1)
[315]. Given that NF-κB is activated by inflammation, hyp-
oxia, and ROS (Section 3.4.1), transcriptional upregulation of
HIF1A by NF-κB and subsequent translation to a functional
unit may be one of the most important regulatory mechanisms
that influences HIF-1 signaling.
HIF-1 activation by COX-2 The intricate relationship be-
tween NF-κB and HIF-1 signaling is further exemplified
through COX-2. In addition to transcriptional regulation by
NF-κB, the PTGS2 gene that encodes COX-2 contains four
HRE sequences in its promoter region, explaining its upregu-
lation by HIF-1 under hypoxic or prooxidative conditions
[201]. Interestingly, COX-2 amplifies the HIF-1 pathway.
COX-2 facilitates the production of PGE2 (Section 3.2.2.1
COX-2), which can subsequently stimulate the transcriptional
activity of the HIF-1 complex [201]. As such, there is a positive
feedback loop for COX-2 andHIF-1 activity, although the exact
molecular interactions have not been fully elucidated.
Fig. 5 Activation of HIF-1α after PDT is mediated by several pathways.
PDT-induced hypoxia due to immediate O2 depletion as well as vascular
shutdown prevents HIF-1α hydroxylation by PHDs and FIH, which is an
O2-dependent process. Furthermore, ROS-mediated oxidation of Fe
2+ in
the catalytic center of PHDs and FIH disables the enzymatic activity of
these proteins. Both events lead to HIF-1α stabilization, translocation
from the cytosol to the nucleus, complexation with HIF-1β, and
transcriptional upregulation of numerous target genes containing an
HRE in the promoter region. HIF-1α transcription is also upregulated
by PDT-activated NF-κB, which increases HIF-1α protein levels. A
negative feedback loop for HIF-1α exists via the upregulation of p53
by activated HIF-1, which targets HIF-1α for proteasomal degradation
in the presence of DNA damage. A positive feedback loop exists via the
upregulation of COX-2 by activated HIF-1 and NF-κB. COX-2 is
involved in the production of PGE2 that plays a role in the
transactivation of HIF-1α. After nuclear translocation, dimerization, and
DNA binding to HRE sequences, HIF-1 transcription factors facilitate the
upregulation of a plethora of genes involved in angiogenesis, survival,
glucose metabolism, proliferation, and apoptosis. Other pathways are
affected as well, but only those most relevant for PDT are depicted
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3.3.2 Downstream effects of the HIF-1 pathway
When the growth of the tumor parenchyma is more extensive
than the formation of new blood vessels, the deficiency in
oxygen supply will trigger HIF-1 activation that in turn signals
a metabolic switch to glycolysis and a consequent decrease in
oxygen demand. The consequent decrease in O2 consumption
expands the area of O2 availability within the tumor, allowing
distally situated tumor cells (relative to the vasculature) to
proliferate, which benefits tumor growth as a whole [297].
Inasmuch as persistent hypoxia can only be resolved by the
formation of new blood vessels, HIF-1 signaling is programmed
to stimulate angiogenesis [316] (Fig. 5). The vascularization of a
tumor requires degradation of the extracellular matrix to enable
vessel sprouting, migration, andmaturation of mesenchymal cells
into endothelial cells; tube formation; and pericyte recruitment to
endothelialize the newly formed lumens (reviewed in [317]).
Therefore, a hypoxic tumor microenvironment and the
HIF-1 transcription factor are important mediators of
cell survival and tumor regrowth following therapy.
With respect to glucose metabolism, tumor cells and tumor-
associated cells become less dependent on oxygen during
hypoxia by reducing oxidative phosphorylation and increas-
ing anaerobic respiration (i.e., glycolysis; Warburg effect)
[318]. HIF-1 is instrumental in this transformation by initiat-
ing the transcription of genes involved in glucose metabolism.
The target gene products include glucose transferases 1 and 3
(GLUT1/3, SLC1A1/3), hexokinase (HK, HK1), lactate dehy-
drogenase A (LDHA), monocarboxylate transporters (MCTs,
SLC16As), pyruvate dehydrogenase (PDH), pyruvate kinase
(PKM), phosphofructokinase L (PFKL), and phosphoglycer-
ate kinase I (PGK1) (reviewed in [297] and [296]) (Fig. 5).
Despite the prevailing state of hyponutrition as a result of
PDT-induced vascular shutdown, residual viable tumor cells
may scavenge glucose from the tumor microenvironment to
support anaerobic respiration. This glucose may have been
released from tumor cells immediately killed by PDT to sup-
port anaerobic respiration. Intratumoral angiogenesis, endo-
thelial cell proliferation, and matrix and vascular remodeling
are modulated by HIF-1 via upregulation of VEGF, endothelin
1 (EDN1), plasminogen activator inhibitor 1 (PAI1,
SERPINE1), (inducible) nitric oxide synthase 2 (NOS2),
angiopoietin (ANGPT) 1 and 2, erythropoietin (EPO), and
transforming growth factor (TGF)-β3 (TGFB3) [299, 319]
(Fig. 5). Proliferation of tumor and tumor-associated cells is
stimulated by HIF-1 through the induction of genes encoding
insulin-like growth factor (IGF) 2 as well as IGF binding
proteins 1, 2, and 3; TGF-α and TGF-β3; and VEGF [296,
297] (Fig. 5). In this process, COX-2, which is a target gene of
HIF-1 (Section 3.3.1.4 HIF-1 activation by COX-2), orches-
trates a positive feedback loop that reinforces the activity of
both COX-2 and HIF-1 [201] (Fig. 5). PGE2 is produced by
COX-2 and enhances HIF1A transcription and induction of
HIF-1, which subsequently binds the COX-2 promoter to up-
regulate its expression [201]. Taken altogether, HIF-1 poten-
tiates numerous critical biological responses to PDT that re-
volve around tumor cell survival and enables cells to cope
with and recover from the damage caused by PDT. Lastly,
HIF-1 has been shown to have notable effects on cell death
pathways. In addition to transcriptionally upregulating
survivin (BIRC5) (Section 3.2.2.2 Survivin) and HO-1 (Sec-
tion 3.1.2), HIF-1 regulates prosurvival proteins of the BCL2
family (BCL2 (BCL2A1), BCL-XL (BCL2L1), BID, and
MCL-1 (MCL1)) (Fig. 5), a lthough proapoptotic
members of the same family have also been reported to be
upregulated by HIF-1, including BCL2-homologous antago-
nist killer (BAK), BAX, BCL2/adenovirus E1B 19 kDa
protein-interacting protein 3 (BNIP3), BNIP3 ligand
(BNIP3L), and NOXA (phorbol-12-myristate-13-acetate-in-
duced protein 1, PMAIP1) [320]. However, HIF-1-mediated
induction of BNIP3 and BNIP3L may also be essential for
hypoxia-driven cytoprotective autophagy and facilitate hyp-
oxic survival, at least in human prostate cancer (PC-3) cells
[321]. Furthermore, HIF-1 has been implicated in the stabili-
zation of tumor suppressor protein p53 [322], which promotes
apoptosis upon oncogenic stress and negatively regulates
HIF-1α stability (Fig. 5) [323]. Although HIF-1 predominant-
ly stimulates survival through various biological processes,
proapoptotic signaling may also occur in the presence of
DNA damage via p53-mediated activation of proapoptotic
BCL2-family members that are upregulated by HIF-1.
3.3.3 Role of the HIF-1 pathway in PDT
AlthoughHIF-1 is considered an important transcription factor in
the context of PDT [17], very few studies have investigated HIF-
1 activity following PDT. Chemical induction of HIF-1 by pre-
incubating human Het-1 esophageal cells with 500 μM CoCl2
desensitized cells to ALA-PDT [324]. Mitra et al. demonstrated
that HIF-1 is activated by porfimer sodium-PDT inmurine breast
cancer (EMT-6) cells transfected with a gene encoding green
fluorescent protein (GFP) under the control of a promoter se-
quence with five HREs [293]. The expression of GFP after
PDT occurred under normoxic conditions, underscoring the rel-
evance of ROS-mediated activation of HIF-1 in the absence of
hypoxia (Sections 3.3.1.2 HIF-1 activation by ROS and 3.3.1.3
HIF-1 activation by NF-κB). The authors argued that PGE2 syn-
thesized by COX-2 (Section 3.3.1.4 HIF-1 activation by COX-2)
may be an important mediator of HIF-1 activity, although no
corroborative evidence was obtained in COX-2 inhibition exper-
iments [293]. The technical difficulties in studying HIF-1 in an
in vitro PDT setting result from the requirement for hypoxic
culture conditions and the short half-life of HIF-1α under
normoxic conditions (5–8 min) [325]. Despite these difficulties,
Krieg et al. showed increased HIF-1α protein expression follow-
ing ALA-PDT in UROtsa, RT112, and J82 (but not RT4) human
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bladder cancer cells under normoxic conditions using reversed
phase protein arrays [292]. Stabilization and activation of HIF-1
under hypoxic conditions was recently demonstrated in human
epidermoid carcinoma (A431) and human extrahepatic cholan-
giocarcinoma (Sk-Cha1) cells after PDT with liposomal zinc
phthalocyanine. In line with HIF-1α stabilization, VEGF,
PTGS2, and HMOX-1 mRNA were upregulated to a greater
extent after PDT than in untreated hypoxic cells (Broekgaarden,
M. et al., Nano Research, in resubmission; Weijer, R. et al.,
Oncotarget, in resubmission). Additional evidence for the prom-
inent role of HIF-1 in PDT was provided in a mouse model of
Kaposi’s sarcoma using porfimer sodium-PDT. Tumors collected
1 h after PDT exhibited increased HIF-1α protein levels com-
pared to untreated tumors. The HIF-1α protein levels in PDT-
treated tumors were comparable to those in tumors of which the
blood supply had been clamped for 30 min [326]. Similar results
regarding HIF-1 activation were obtained in human nasopharyn-
geal carcinoma (CNE-2) xenografts in mice that had been sub-
jected to hypericin-PDT [246] and in rat chorioretinal tissue treat-
edwith verteporfin-PDT [294]. The increasedmRNAexpression
and protein levels of HIF-1α were associated with increased
protein levels of VEGF, as was demonstrated in a murine model
ofmammary (BA) carcinoma treatedwith porfimer sodium-PDT
[291], indicating that post-PDT HIF-1 signaling induces angio-
genic remodeling of the affected tissue (Section 3.3.2 and Fig. 5).
Moreover, a clinical study by Koukourakis et al. revealed that
esophageal tumors with high intratumoral protein levels of HIF-1
were more resistant to PDTcompared to tumors with low HIF-1
protein levels [327], attesting to the involvement of HIF-1-
mediated survival pathways following PDT (Section 3.3.2 and
Fig. 5). Increased HIF-1α protein levels were also observed in
mouse porfimer sodium-PDT-treated murine BA mammary car-
cinoma tumors, but this was not reported for porfimer sodium-
PDT-treated BA cells in vitro [250].
3.3.4 Inhibition strategies for HIF-1 and its downstream
targets
Due to the importance of HIF-1 in tumor survival, therapeutic
interventions for cancer encompass the inhibition ofHIF-1 [290].
However, most HIF-1 inhibitors are rather unspecific and also
target the upstream modulators of HIF-1α protein synthesis, of
which imatinib (an inhibitor of breakpoint cluster region protein
(BCR)-ABL [328]), gefitinib, erlotinib, and cetuximab (an inhib-
itor of EGFR [329]), and everolimus (an inhibitor of mTOR
[330]) are well-known examples [290] (Table 1). Another com-
bination strategy is to interfere with the stabilization of HIF-1 by
inhibition of chaperone binding using geldanamycin (an inhibitor
of HSP90 [331]) or increasing the affinity for natural inhibitors of
HIF-1 (e.g., amphothericin B [148]) (Table 1). Interfering with
HIF-1 DNA binding is another approach to reduce HIF-1 signal-
ing. For example, echinomycin competes with HIF-1 to bind to
HREs and can therefore be used to reduce transcriptional
activity of HIF-1 [149] (Table 1). Asmentioned previously, these
inhibitors are rather unspecific, which may be valuable in the
development of a combinatorial cancer therapy.However, amore
specific inhibitor of HIF-1would be desirablewhen investigating
the mechanism of HIF-1 on tumor cell survival following PDT.
α-Ketoglutarate may be a useful drug as a specific inhibitor of
HIF-1 (Table 1). Under normophysiological conditions, PHDs
are themajor inhibitors of HIF-1 activity during normoxia but are
rendered dysfunctional during hypoxia [332] (Section 3.3.1 and
Fig. 5). The endogenous molecule α-ketoglutarate is a selective
PHD substrate and agonist [312], and it is able to reactivate
PHDs to inhibit HIF-1 regardless of intracellular oxygen tension
[141]. Under normoxic conditions, PHDs facilitate the conver-
sion of α-ketoglutarate and oxygen to succinate and carbon di-
oxide, respectively, but also transfer oxygen to prolyl residues in
the HIF-1α oxygen-dependent degradation domain (ODD)
[312]. Increasing the activity of PHDs after PDT with α-
ketoglutarate may therefore render cells less susceptible to HIF-
1-mediated survival. Studies by Mackenzie et al. have shown
that, despite hypoxia, the activity of PHD2 and 3 and the con-
current destabilization of HIF-1 in various tumor cell lines and
murine xenografts could be induced by the administration of α-
ketoglutarate esters (esterification allows passage through the
membrane into the cell) [141]. The inhibition of HIF-1 by α-
ketoglutarate was associated with decreased tumor growth and
increased apoptosis [277, 333]. Based on these investiga-
tions, HIF-1 inhibition by α-ketoglutarate may be a
valuable strategy in potentiating the effects of PDT.
However, recent studies by our group revealed that α-
ketoglutarate did not increase the efficacy of PDT, but
rather reduced PDT-induced oxidative stress as mea-
sured 4 h post-PDT in A431 cells. It was hypothesized
that α-ketoglutarate was used as an energy source to
fuel antioxidant responses or that it functions as an an-
tioxidant itself and thus is not a suitable agent to en-
hance the PDT response (Broekgaarden, M. et al., Nano
Research, in resubmission; Weijer, R. et al., Oncotarget,
in resubmission).
Another nonspecific inhibitor of HIF-1 is the naturally oc-
curring diphenolic compound curcumin (Table 1), which was
found to promote proteasomal degradation of HIF-1α and
HIF-1β (also known as aryl hydrocarbon receptor nuclear
translocator, ARNT) [150, 334, 335]. Moreover, Choi et al.
[150] showed that HIF-1 activity was reduced as a result of
curcumin-stimulated oxidation and proteasomal degradation
of HIF-1β. The authors further showed that the inhibition of
HIF-1β was dependent on oxidation, as addition of the
antioxidant N-acetylcysteine prevented HIF-1β inactivation
by curcumin. However, it should be noted that curcumin
exerts many other mainly cytostatic/toxic effects on tumor
cells, including the inhibition of EGFR tyrosine kinase
activity and downstream signaling; inhibition of protein
kinase C, COX-2, and NF-κB; and induction of DNA
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damage [336]. These effects tend to increase PDT efficacy,
as exemplified by the finding that curcumin increases
ROS production, mitochondrial membrane perme-
abilization, mitochondrial cytochrome c release, and cas-
pase activation after porfimer sodium-PDT, which exacer-
bated cell death in human head and neck cancer (AMC-
NH3) cells [337]. In contrast, curcumin is also a potent
antioxidant [336], a property that was found to reduce the
extent of ROS production and thereby the degree of cell
death in A431 human epidermoid carcinoma cells treated
with rose bengal-PDT [338].
A recently discovered and rather specific inhibitor of HIF-1
activity is acriflavine (Table 1), which inhibits HIF-1α/HIF-
1β and HIF-2α/HIF-1β dimerization by binding the Per-Arnt-
Sim B domain of HIF-1α and HIF-2α [151]. The binding of
acriflavine to HIF-1 blocks DNA binding and reduces tran-
scriptional activity, tumorigenicity, and angiogenic signaling,
as was demonstrated in xenotransplanted human prostate (PC-
3) and hepatoma (Hep3B) tumors in mice [151]. Results from
our lab confirm the feasibility of employing acriflavine to
improve PDT efficacy, as the sensitivity of A431 cells to
PDT increased as a result of reduced glycolytic activity;
downregulation of the HIF-1 target genes VEGF, PTGS2,
and PAI1; and upregulation of EDN1. Taken together, these
results illustrate the importance of HIF-1 in the protection of
tumor cells from PDT (Broekgaarden, M. et al., Nano Re-
search, in resubmission; Weijer, R. et al., Oncotarget, in
resubmission).
3.3.5 Concluding remarks
The HIF-1 transcription factor is essential for the survival of
cells in a hypoxic environment and under conditions of acute
stress, such as oxidative stress induced by PDT. The survival
signaling manifests itself through direct intracellular events
(e.g., by the production of prosurvival proteins and the shift
to oxygen-independent metabolism) as well as through tissue
processes (e.g., angiogenesis and proliferation) (Section 3.3.2).
In case of PDT, it has been shown that HIF-1 activation causes
the release of proangiogenic factors (Section 3.3.3).
Since malignant tumors proliferate faster than the rate
of neovascularization, most tumors are hypoxic in na-
ture and constitutively activate HIF-1 [316]. Poorly
vascularized tumors may therefore be more resistant
against PDT due to hypoxic preconditioning (in addition
to the suboptimal accumulation of systemically adminis-
tered photosensitizer molecules as a result of the poor
blood supply). Tumors that overexpress HIF-1 are less
sensitive to therapy and are associated with poor surviv-
al in patients. Accordingly, the coadministration of HIF-
1 inhibitors as neoadjuvants increases the efficacy of
PDT, as has been demonstrated in several studies
(Section 3.3.4).
3.4 The ASK1 pathway
The immediate early stress response is a mechanism in cells
that encompasses the rapid transcription and translation of a
set of genes coding for protein products that enable cells to
adequately adapt to extra- or intracellular stress. Although the
exact activation trigger fueling this response is somewhat elu-
sive in relation to PDT, this section reviews the activation of
ASK1 in response to generic oxidative stress, similar to that
induced by PDT, and to TNF-α signaling (Section 3.4.1).
ASK1 relays its signal via MAPKs (JNK and p38MAPK) to
the AP-1 transcription factor family (Section 3.4.2.1.1 JNK
and p38 proteins) that is responsible for the rapid induction of
immediate early gene transcription. As a whole, the ASK1
signaling pathway exerts both cytoprotective as well as
cytodestructive effects, depending on the balance between
the activation of the ASK1 pathway and the NF-κB-TNF-α
pathway that seem to chiefly govern cell fate (Section 3.2).
The available literature on the participation of the ASK1 path-
way in the post-PDT response (Section 3.4.5) and inhibition of
MAPK activity (Section 3.4.4) are summarized, and possible
inhibition strategies for this survival pathway are proposed.
3.4.1 Activation mechanisms of ASK1
ASK1 activation by ROS The activation of JNK, p38MAPK,
and AP-1 transcription factors following oxidative stress is
preceded by the activation of the mitogen-activated protein
kinase kinase kinase ASK1 [339]. ASK1 forms homo-
oligomers in its inactive state, comprising a complex that is
referred to as the signalosome, in which multiple ASK1 pro-
teins are bound at their C-terminal coiled-coil domains [340].
Thioredoxin (TRX) binds ASK1 subunits of the signalosome
that shield the N-terminal transactivation domain, thereby
inhibiting autophosphorylation of threonine (Thr) 845 that is
required for signalosome activation [341]. Under oxidative
stress (e.g., after TNF-α-induced ROS formation), ROS (and
oxidized substrates such as proteins and GSSG) mediate the
oxidation of TRX [342]. TRX is oxidized at cysteine residues
in the active site, leading to its dissociation from the
signalosome, subsequent autophosphorylation of ASK1 sub-
units, and activation of the complex [339, 341, 343] (Fig. 6).
Activated ASK1 phosphorylates MAP kinase kinases
(MKK3), MKK4, MKK6, and MKK7 at conserved residues
within the kinase domain, leading to their activation [344,
345]. MKK4 and MKK7 phosphorylate and activate JNK at
Thr183 and Thr185, whereas MKK3 and MKK6 phosphory-
late and activate the different p38MAPK isoforms
(Section 3.4.2.1 Acute downstreameffects of ASK1 activa-
tion) at Thr180 and Tyr182 [346, 347]. In addition to direct
activation via oxidized TRX, ASK1 signaling may be
enhanced via paracrine signaling through TNF-α, as is
described in the following section.
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ASK1 activation by TNF-α The ASK1 pathway is also stim-
ulated by TNF-α (Fig. 6), which is expressed as a result of PDT-
activated AP-1 and NF-κB transcription factors, and TNF-α is a
potent inducer of apoptosis and programmed necrosis (reviewed
in [184]). TNF-α binds to the TNFR, which in turn mobilizes
TRAFs 2, 5, and 6 to bind and activate the ASK1 signalosome
[340]. ASK1 activation can also be triggered by TNF-α signaling
alone [340] as a result of TNF-α-mediated production of ROS by
mitochondria and/or NADPHoxidase 1 [348, 349]. ROS produc-
tion by TNF-α likely involves TRAF2 [350].
3.4.2 Downstream effects of ASK1 activation
Acute downstream effects of ASK1 activationAlthough the
exact role of ASK1 itself is underinvestigated in the context of
PDT, the ASK1 signaling cascade has been implicated in both
increasing cell death and increasing cell survival in response
to ROS or TNF-α. Whereas a transient activation stimulus
(i.e., short-lasting or mild oxidative stress) encourages surviv-
al and proliferation [351], a prolonged activating stimulus
(i.e., severe and prolonged oxidative stress or prolonged
TNF-α/TNFR signaling) promotes growth arrest and apopto-
sis [352] (Fig. 8). Since the MAPKs JNK and p38MAPK can
regulate both survival (via a plethora of AP-1-like transcrip-
tion factors) and cause cell death (via the activation of
proapoptotic BCL2 proteins), we postulate that these kinases
are critical for this cell survival/death switch or checkpoint, as
is discussed below and summarized in Fig. 7.
JNK and p38 proteins There are three JNK isozymes, name-
ly JNK1, JNK2, and JNK3, whereby JNK3 is mainly
expressed in neural tissue. JNK mRNA is prone to alternative
splicing, giving rise to over 10 different isoforms, which ex-
plains the diverse biological functions in various tissues [353,
354]. Whereas JNK1 was found to be the most important
inducer of downstream signaling and JNK2 is an antagonist
that competes with JNK1 for ligand binding [355], a more
activating role of JNK2 in downstream signaling induction
has also been described [356]. Since most inhibition strategies
for JNK signaling were performed with JNK1 inhibitors, the
focus will be on this specific isozyme of the JNK family.
Although there are four isoforms of p38MAPK proteins, name-
ly p38α, p38β, p38δ, and p38γ, the functions of p38α and
p38β are most extensively described [354]. Many inhibition
strategies regarding p38MAPK and downstream signaling
events were performed with inhibitors for p38α and p38β,
so the main focus for the remainder of this review will be on
these specific isozymes of the p38MAPK family.
AP-1 transcription factors JNK1 and p38α/β activate a mul-
titude of AP-1-type transcription factors. The AP-1 transcrip-
tion factor family consists of a large variety of dimers com-
posed of basic leucine zipper domain (bZIP) proteins from the
Fig. 6 Activation mechanisms of the ASK1 signaling pathway leading to
JNK and p38MAPK phosphorylation. ROS can directly or indirectly (via
GSH) oxidize the TRX subunits (TRX-ox) of the inactivated signalosome
complex. Upon oxidation and subsequent dissociation of TRX, the ASK1
heteromer autophosphorylates and initiates downstream signaling.
MKK4/7 are kinases responsible for the activation of JNK proteins,
whereas MKK3/6 phosphorylate and activate the p38MAPKs.
Downstream of the NF-κB, HIF-1, and FOS pathways, tumor cells and
immune cells produce TNF-α. TNF-α binds the TNFR, which activates
intracellular TRAF. These TRAFs stimulate the production of
mitochondrial ROS and NADPH oxidase 1-derived ROS that stimulate
the dissociation of TRX from the signalosome, but also bind TRX to
prevent reassociation of TRX with ASK1
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JUN subfamily (JUN, JUNB, and JUND), the ATF2 subfam-
ily (ATF2 and cAMP response element binding, CREB), and
the FOS subfamily (FOS, FOSB, FOS-related antigen 1
(FRA1), and FRA2). Another subfamily exists, the MAF sub-
family [262], but the function of these proteins in the cellular
response to PDT or oxidative stress remains largely
unexplored.
As addressed above, JNK1 specifically phosphorylates and
activates AP-1 proteins from the JUN and ATF2 subfamilies as
well as the non-AP-1 transcription factor ETS domain-
containing protein (ELK-1). Other transcription factors such as
NRF2 and p53 are phosphorylated and activated by JNK1.
p38α/β also phosphorylates JUN and ATF2 proteins and also
functions as a kinase for FOS proteins. Moreover, p38α/β phos-
phorylates NRF2 [85] although the inhibitory effects of p38α/β
on NRF2 have been reported [357]. Phosphorylation of
myocyte-specific enhancer factor 2 (MEF2) and CCAAT-
enhancer binding protein (C/EBP)β [354] has also been reported,
thereby triggering the expression of a plethora of genes involved
in cell type-specific differentiation. However, AP-1-type tran-
scription factors constitute the main targets for these MAPKs,
and a more elaborate description of the target genes of these
transcription factors is provided below.
Proliferation JUN and ATF2 stimulate cell proliferation by
upregulating the production of cyclins D, E, and A;
EGFR; heparin-binding EGF (HBEGF); and keratinocyte
growth factor (KGF) [358–361]. Additionally, cell cycle
inhibitors p53, p19ARF, and p21CIP1 are downregulated by
JUN [362–365]. Contrastingly, JUN and ATF2 also up-
regulate several cell cycle inhibitors such as the retino-
blastoma 1 protein (RB1), GADD 45α and β, and
p16INK4A [366, 367].
Angiogenesis and invasion Stimulation of angiogenesis and
invasion are the result of proinflammatory cytokines, growth
factors, and extracellular matrix modifiers that ultimately
stimulate tumor regrowth. ATF2 and FOS appear to play ma-
jor roles in the production of proteins involved in these path-
ways. Moreover, c-FOS is subject to upregulation by CREB, a
member of the ATF2-like subfamily, which amplifies the FOS
pathway [368]. FOS stimulates inflammation by facilitating
the production of VEGF, urokinase-type plasminogen activa-
tor (uPA), uPA receptor (uPAR), MMP1, MMP3, methionyl-
tRNA synthetase 1 (MTS1), Kelch-related protein 1 (KRP1),
ferritin repressor protein (FRP), ezrin (EZR), and tropomyosin
(TPM) 3 and 5b (reviewed in [262]). ATF2 further contributes
to the generation of a proinflammatory state by mediating the
production of platelet derived growth factor receptor A
(PDGFRA) [369], MMP2 [370], TNF-α [371], IFN-γ [372],
and HSP90A5 [373]. In addition, CREB also induces many
cytokines such as IL-2, IL-6, IL-10, and TNF-α to cause in-
flammation that in turn stimulates angiogenesis and invasion
[374]. Besides directly stimulating apoptosis, many of the
abovementioned cytokines are involved in stimulating im-
mune cells to release a multitude of angiogenic factors via
NF-κB (Section 3.2) and AP-1 transcription factors
(Section 3.4).
Fig. 7 JNK1 exerts kinase activity on several transcription factors and
BCL2 family proteins through phosphorylation (P) or ubiquitination (U).
Proliferation and inflammation are induced by phosphorylating members
of the JUN and ATF2 protein family, as well as ELK-1. The NRF2
antioxidant response is triggered via phosphorylation of NRF2 at Ser40.
Apoptosis is stimulated via the phosphorylation of BAX, BAK, BIM,
BID, and BMF proteins as well as via p53 activation. Antiapoptotic
proteins are also phosphorylated (and inactivated) by JNK1, which
include BCL2, BCL-XL, and MCL-1, or ubiquitinated (c-FLIP). The
kinase functions of p38α/β entail a similar effect on the NRF2
antioxidant response pathway as reported for JNK1. Inflammation is
stimulated via phosphorylation of the AP-1 transcription factors of the
FOS and C/EBP protein family. Proliferation and survival are promoted
via activation of JUN andATF2. Translation of newly transcribed genes is
facilitated by phosphorylation of MSK1, MNK1, and MNK2.
Differentiation is mediated via MEF2 activation by p38α/β.
Additionally, p38α/β regulate the cell cycle by phosphorylation of
MK2 and MK5
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Apoptosis In addition to stimulating inflammation and prolifer-
ation, AP-1 transcription factors also regulate apoptosis follow-
ing an oxidative insult. JUN regulates the transcription of
antiapoptotic BCL2 family members BCL2, BCL3, BCL-XL,
and the proapoptotic BIM [262], the eventual result depending
on the extent of damage and the cross-talk between various path-
ways. Additionally, both JUN and FOS stimulate the extracellu-
lar apoptosis pathway by upregulating FAS ligand and FAS re-
ceptor (FASR) [262, 375], whereas ATF2 induces the production
of TNF-related apoptosis-inducing ligand (TRAIL) [371]. Given
the variety of different genes and processes influenced by the
AP-1 transcription factor family and the overlap of genes that
different family members can induce, the exact effects of AP-1
on overall tumor cell survival or cell death induced by PDT
remain difficult to predict. This is because although AP-1 may
stimulate tumor growth and survival by mediating cell cycle
progression, inflammation, angiogenesis, and migration, AP-1
may also be instrumental in the induction of apoptosis via the
upregulation of FAS, FASL, and TRAIL, as well the differential
regulation of BCL2 protein family members.
Additional effects of p38 MAPK To assist in transcription,
p38MAPK activates mitogen- and stress-activated protein ki-
nases (MSK) 1 and 2 that phosphorylate histone H3 to en-
hance chromatin remodeling and transcription factor binding
to DNA [376]. The activation of MAPK interacting kinases
(MNK) 1 and 2 by p38MAPK further facilitates mRNA trans-
lation by phosphorylating the eukaryotic translation initiation
factor (EIF)4E that binds RNA and targets it to ribosomes
[377], whereas MSK1 contributes to mRNA translation by
inactivating the EIF4E inhibitor 4E-binding protein 1
(4EBP1) [378]. Other functions of MSK1/2 include the phos-
phorylation and activation of transcription factors ATF1,
CREB [379], as well as several other transcription factors
(e.g., NF-κB, ETS variant 1, and high mobility group nucle-
osome binding domain 1). Through these transcription factors,
MSKs upregulate the transcription of JUN and FOS [379] and
contribute to inflammation and survival by upregulating IL-6
and RELA (see NF-κB, Section 3.2) [376].
p38α/β activity appears to stimulate cell motility by phos-
phorylation of MAPK-activated protein kinases 2 and 5
(MK2, MK5) [380]. When activated by p38MAPK, these ki-
nases phosphorylate HSP27, causing HSP27 dimerization and
consequent binding to the actin cytoskeleton—a phenomenon
associated with heightened cell motility in human umbilical
vein endothelial cells [381]. Thus, this activity of p38α/βmay
stimulate tumor cell survival by promoting angiogenesis, in-
vasion, and metastasis.
p38α/β can have positive and negative effects on the cell
cycle through the activation of MK2 and 5. MK2 halts the cell
cycle by phosphorylating and activating the cell division cycle
(CDC) proteins CDC25B andCDC25C,which can functionalize
the G2/M checkpoint and arrest the cell cycle in the presence of
DNA damage. MK5 promotes senescence by phosphorylating
p53 and inhibiting the expression of c-MYC, but also stimulates
proliferation by sequestering ERK3 in the cytoplasm [382].MK2
negatively regulates p53 by phosphorylating the p53 ubiquitin
ligase MDM2 (mouse double minute 2, human homologue) and
inhibits CDCs to stimulate proliferation despite DNA damage
(reviewed in [383]). Other, but less studied effects of p38MAPK
include the upregulation of HIF-1α [384] and COX-2 [385]
(Sections 3.2 and 3.3), suggesting a survival-promoting role for
p38MAPK. This has been corroborated in a recent study by Rubio
et al., in which p38MAPK was implicated in the removal of ubiq-
uitin aggregates via autophagy and activation of NRF2 after
hypericin-PDT that led to increased survival of fibroblasts [386].
Prolonged downstream effects of ASK1 activation
Prolonged activation of JNK stimulates apoptosis. Prolonged
JNK1 activation is a signal for extensive cell damage that
triggers apoptosis via TNF-α and degradation of the caspase
8 inhibitor CFLAR [387, 388]. Apoptosis is further promoted
through the inhibition of antiapoptotic BCL2 protein family
members BCL2, BCL-XL, and MCL-1 [389, 390] in combi-
nation with activation of proapoptotic BAX, BAK, BIM,
BCL2-modifying factor (BMF), and BID (yielding JNK-
cleaved BID or jBID) [391–393]. In addition, JNK1 stabilizes
the tumor suppressor protein p53 to stimulate apoptosis and
cell cycle arrest in response to DNA damage [345, 394].
Prolonged activation of JNK1 and consequent cell death sig-
naling is induced by prolonged oxidative stress, depleted an-
tioxidants and impaired survival responses (e.g., reduced ac-
tivity of NRF2 and NF-κB), or TNF-α signaling combined
with oxidative stress (Fig. 8). Similarly, in response to phorbol
12-myristate 13-acetate and ionomycin, transient activation of
JNK1 was associated with survival of human Jurkat T-cells,
whereas prolonged activation of JNK1 (phorbol 12-myristate
13-acetate, ionomycin, and UV-C irradiation) induced cell
death [395]. In primary rat mesangial cells, TNF-α treatment
alone induced transient JNK1 activation that did not result in
loss of cell viability. Conversely, a combined treatment of
TNF-α with either actinomycin D or cycloheximide resulted
in prolonged JNK1 activation and major decreases in cell
viability [396]. With the use of mouse embryonic fibroblasts
(MEFs) derived from Traf2−/− and Traf6−/− mice, Noguchi
et al. revealed that Traf2 and Traf6 (typically activated via
TNFR) were essential for the induction of H2O2-induced cell
death [340], thereby indicating that simultaneous exposure of
cells to TNF-α/TNFR signaling and oxidative stress may fa-
cilitate prolonged ASK1 signaling with sustained activation of
JNK1. ROS were an essential second messenger for TNF-α-
induced apoptosis in murine L929 cells, as the induction of
apoptosis in murine L929 cells following combined H2O2 and
TNF-α treatment could be completely prevented by the anti-
oxidant N-acetylcysteine [341]. TNF-α inhibi ted
ASK1/TRX interaction [341]—most likely via binding
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of TRAFs [340]—which could be reversed upon the
addition of N-acetylcysteine, suggesting an essential
role for oxidants in the induction of TNF-α-mediated apoptosis
[341]. Downstream of TNF-α, TRAF2 and RIP1 induced apo-
ptosis inMEFs via JNK1 activation, although the involvement of
ASK1 itself was not investigated [397]. The induction of cell
death via TNF-α was prevented when NF-κB was activated in
MEFs [350]. NF-κB decreased TNF-α-induced ROS formation,
thereby preventing prolonged JNK1 activity and consequent cell
death in MEFs [189]. A similar effect was found using PDT, in
which inhibition of NF-κBwith Bay 11-7082 in human glioblas-
toma cells augmented TNF-α-induced tumor cell death follow-
ing PDT [273]. However, the induction of necrosis by ALA-
PDT of human glioblastoma cells occurred via RIP1 and RIP3
in an NF-κB-independent manner [64].
Induction of transient JNK1 activity prevents apoptosis
Several downstream genes regulated by NRF2 and
NF-κB in turn affect the transient activity of JNK1 by
inhibiting its function to facilitate cell survival (Fig. 8). Since
these gene products need to be transcribed and translated be-
fore being able to downmodulate JNK1, there is a time period
during which JNK1 is active. GSTp is produced downstream
of the NRF2 pathway and inhibits JNK1 to stimulate cell
survival [398–402] or else transiently inactivates p38MAPK
to mediate survival of oxidatively stressed murine 3T3 fibro-
blasts [402]. Moreover, the NF-κB and AP-1 target genes
GADD45α and β limit the activity of JNK1 by binding and
inhibiting MKK7 and 4 [403, 404]. Conversely, GADD45α
and β increase the activity of p38MAPK, whereby the combined
effects of JNK1 inhibition and p38 activation protected hemato-
poietic cells from UV-induced apoptosis [403]. Upregulation of
A20 and XIAP by NF-κB leads to blocked JNK1 activity via an
unknown mechanism (reviewed in [405]).
3.4.3 Role of the ASK1 pathway in PDT
Direct ASK1 activation following PDT has never been
demonstrated, so the involvement of this pathway in re-
sponse to PDT can only be deduced from the effects on
downstream kinases and transcription factors. Considerable
increases in c-FOS and c-JUN mRNA levels were found
after porfimer sodium-PDT of RIF-1 cells. Levels of
mRNA peaked 90 min post-PDT, after which mRNA
levels gradually dropped to baseline during the subsequent
8 h [406]. Furthermore, protein kinase inhibitors such as
staurosporine effectively blocked the synthesis of c-FOSmRNA,
hinting toward the involvement of upstream kinases p38MAPK
and JNK [406]. Activation of JNK and p38MAPK, but not other
MAPKs such as ERK1 or ERK2, in benzoporphyrin derivative-
PDT-subjected murine PAM212 keratinocytes confirmed the in-
volvement of the AP-1 response. The activation of JNK and
p38MAPK was abrogated in the presence of antioxidants [407].
Activation of the AP-1 response in the PAM212 keratinocytes
was further confirmed by ATF2 and JUN phosphorylation fol-
lowing PDT [407].
Fig. 8 The ambivalent effects of the ASK1 pathway are dictated by the
cross-talk between various pathways and the prevailing biochemical
conditions. The primary activation mechanism of the ASK1 pathway by
PDT emanates from oxidative stress or TNF-α signaling, leading to the
acute, survival-promoting activity of JNK1 and p38α/β. Subsequently,
downstream of the NRF2 and the NF-κB pathways, negative regulators
of JNK1 and p38α/β are produced/activated that modulate the transient
activation pattern of these kinases and thus promote cell survival.
Whenever ROS and TNF-α signaling occur simultaneously, or
whenever these stress signals endure, prolonged JNK1 and p38α/β
activation promotes apoptosis
668 Cancer Metastasis Rev (2015) 34:643–690
3.4.4 Inhibition strategies of ASK1 and its downstream targets
Since the discovery of their involvement in the response to
PDT, the effects of the MAPKs and AP-1 proteins on the
biological fate of PDT-affected cancer cells have been elusive
or inconsistent. Two types of approaches can be used to inhibit
the ASK1 pathway. The first approach is to inhibit the func-
tion of AP-1 transcription factors, while the other method
prevents AP-1 activation through inhibition of the upstream
kinases JNK and p38MAPK. Direct chemical inhibition of AP-
1 transcription factors is possible with retinoic acid and its
analog SR11302 (Table 1). More specifically, retinoic acid
or retinoic acid analogs are able to inhibit ATF2 [408] and c-
Jun [409]. It was shown that these inhibitors were efficient in
blocking AP-1 activity, which prevented tetradecanoyl
phorbol acetate-induced papilloma formation in mice [152,
410]. This illustrates the potential for a treatment modality in
which retinoic acid is used to sensitize tumor cells to PDT.
However, to date no studies have employed direct inhibition
of AP-1 in conjunction with PDT.
Indirect inhibition of AP-1 activation has been
achieved with inhibitors of JNK and p38α/β. JNK1 can
be inhibited by the anthrapyrazole SP600125 (Table 1),
even though this compound also mildly impairs the func-
tion of p38β and ERK2 [153]. The pyridinyl imidazole
derivatives SB202190, SB203580, and PD169316 have
been used for the selective inhibition of p38α/β, but not
the δ or γ isozymes (Table 1). The JNK and p38MAPK
inhibitors all compete with ATP for the ATP-binding do-
main of the kinases, resulting in the reversible inhibition
of kinase activity [154]. However, the roles of these ki-
nases are rather unpredictable and the effects of inactiva-
tion are dependent on the cell type and the extent of dam-
age. The contradictory effects that these MAPKs can have
on tumor cell survival following PDT are shown in
Table 2. The data reveal that p38MAPK and JNK induce
both survival and apoptosis but also suggest that the inhi-
bition of p38α/β augments tumor cell death, whereas in-
hibition of JNK either has no effect or impairs PDT-
induced cell death. This is in line with the dichotomous
effects of JNK1 activation and the cytoprotective function
of p38α/β as described in Section 3.4.2.2 Prolonged
downstream effects of ASK1 activation, in which
p38α/β mainly functions as activator of AP-1 and facili-
tators of transcription. Therefore, it can be deduced that
JUN and ATF2 (both downstream of JNK) do not play a
significant role in cell survival, but FOS (only activated
by p38MAPK) may in fact be a decisive factor for cell
survival. Alternatively, in a recent study by Rubio et al.,
p38MAPK was implicated in the removal of ubiquitin ag-
gregates via autophagy and activation of NRF2 after
hypericin-PDT, which resulted in increased survival of
fibroblasts [386].
3.4.5 Concluding remarks
The ASK1 pathway is one of the most complicated pathways
activated by PDT. Although ASK1 itself has, to our knowl-
edge, never been investigated in the context of PDT, many of
its downstream targets have often been implicated in cellular
responses to PDT. However, the effects of this pathway are
highly divergent, ranging from stimulation of survival to caus-
ing inflammation and stimulation of cell death. It is arguable
that JNK1 has a particularly important role in the stimulation
of apoptosis in cells exposed to severe and prolonged oxida-
tive stress or concomitant TNF-α signaling. Experimental ev-
idence regarding the inhibition of JNK-1 and p38α/β is in
agreement with this hypothesis. Survival signaling as a result
of transient JNK and p38MAPK activity may arise from the
phosphorylation of AP-1 transcription factors and the trigger-
ing of the immediate early survival response. Therefore, given
the dichotomous nature of the ASK1-MAPK pathway, it is
hypothesized that pharmacological inhibition of AP-1 tran-
scription factor activation could improve PDT efficacy, while
the function of the MAPKs JNK and p38MAPK should remain
intact.
3.5 The proteotoxic stress response
ROS production by PDT primarily results in the oxidation of
lipids and proteins, leading to protein misfolding or formation
of protein aggregates [27]. These forms of proteotoxic stress
trigger transcriptional responses that are collectively known as
the UPR, which is considered a form of ER stress. The UPR is
mediated by several transcription factors that include inositol-
requiring protein 1 (IRE1), ATF6, and protein kinase RNA-like
ER kinase (PERK). Although generally not included as a part of
the UPR, unfolded proteins generated as a result of oxidative and
proteotoxic stress also activate HSF transcription factors, which
aid in alleviating ER stress [419]. The HSF transcription factors
facilitate an adaptive response that enables protein refolding and
degradation of protein aggregates via the upregulation of chap-
erones and inhibition of protein neogenesis (reviewed in [420]).
It can be seen that, when the adaptive responses to
unfolded proteins and ER stress are constitutively active
in tumor cells, the threshold for the ROS-mediated induc-
tion of cell death will be higher. HSFs trigger the produc-
tion of HSPs to assist in protein refolding, protein com-
plex formation, or protein degradation to alleviate the
proteotoxic stress [421, 422]. Clinical evidence has shown
that HSF1 and its downstream products HSP27, 70, and
90 are often constitutively activated in tumors [423]. The
same constitutive activation was found for components of
the IRE1 and PERK pathways [424], thus pointing toward
a predisposition of tumor cells to be able to cope with
PDT-induced proteotoxic stress.
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3.5.1 Activation mechanisms of the proteotoxic stress
response
Of the four HSFs isoforms 1–4, HSF1 is the most important
[421] and will be discussed in the context of the proteotoxic
stress response. Under nonstressed conditions, HSF1 forms
inactive monomers in the cytoplasm that are acetylated by
p300/CREB binding protein (CBP). HSP40, 70, and 90 form
complexes with HSF1 and negatively regulate either its
transactivation mechanism (HSP90) or its DNA-binding ca-
pacity (HSP40 and HSP70) [421, 425]. Whenever HSPs need
to be engaged to combat proteotoxic stress by ROS or hypox-
ia, HSPs dissociate from the HSF complex and bind to
misfolded proteins. This binding relieves the negative regula-
tion of HSF, leading to HSF homotrimerization and activation
[421]. Moreover, stress-induced sirtuin (SIR2) deacetylates
HSF and maintains the complex in a state capable of binding
DNA [425] (Fig. 9). Additionally, JNK2 has been implicated
in phosphorylating the transactivation domain of HSF1, con-
tributing to its activation and subsequent binding to genomic
Fig. 9 Mechanism of HSF1 activation. Monomeric HSF1 is kept
inactive in the cytosol via acetylation by p300/CREB binding protein.
The cytosolic monomers interact with HSP40, 70, or 90, which prevents
DNA binding and transactivation. Proteotoxic stress titrates HSPs away
from HSF1 and stress-induced SIR2 deacetylates the HSF1 monomers.
Subsequently, HSF1 forms homotrimers, translocates to the nucleus, and
binds genomic heat shock elements to facilitate target gene expression.
The target gene products are mainly involved in protein (re)folding, but
also enforce the immediate early stress response and inflammationT
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heat shock elements [426]. Other sensors of the ER stress
response include IRE1, ATF6, and PERK. These proteins
are embedded in ER membranes and are activated when their
chaperones (mainly HSP70A5, also known as glucose-
regulated protein 78 (GRP78) and binding immunoglobulin
protein (BIP)) are recruited away to bind to unfolded proteins
(Fig. 10).
3.5.2 Downstream effects of HSF1, IRE1, PERK, and ATF6
HSF1 HSF1 induces the expression of a plethora of heat
shock proteins (including but not limited to HSP27, HSP40
(DNAJ), HSP70, and HSP90 [427]), which are molecular
chaperones that assist in the folding, translocation, and com-
plexation of newly translated proteins (Fig. 9). Increased ex-
pression of HSPs enhances the survival of cells that have been
stressed by prooxidative conditions, hypoxia, or chemothera-
peutic agents [428]. Consequently, the constitutive activation
of the heat shock response in tumors (as a result of constitutive
mild stress) is frequently observed and protects tumor cells
from the cytotoxicity involved in different kinds of cancer
therapy (chemotherapy, radiotherapy, and PDT) [429, 430].
HSF1 also induces JUN and FOS (Fig. 9), thereby reinforcing
the AP-1-induced immediate early stress response
(Section 3.4.2.2 Prolonged downstream effects of ASK1 acti-
vation) [431, 432]. Other, less studied effects of HSF1 are the
induction of IL6 (Fig. 9) and the consequent transcriptional
repression of TNFA, IL1B, NOS2, CCL5, IL8, C5, and ICAM1
by inhibiting NF-κB activation (reviewed in [433]). The
HSF1 pathway most likely raises the level of intracellular
stress necessary for IKK activation and IκBα degradation that
are required to activate NF-κB [433]. The reduction of
proteotoxic stress emanating from oxidatively modified
proteins has been attributed to the chaperone function of
HSPs, which tend to prevent protein denaturation and aggre-
gation, assist in the correct refolding of affected proteins, pro-
mote GSH reduction, and maintain proteasome function
(reviewed in [428, 429, 434]). Moreover, HSP70 prevents
apoptosis by reducing JNK1 phosphorylation and BID-
mediated mitochondrial membrane permeabilization;
preventing caspase 8 activation by FADD; lessening the mi-
tochondrial localization of BAX; inhibiting cleavage of
procaspases 3, 7, and 9; and binding apoptosis-inducing factor
(AIF) and a variety of other apoptotic effectors [429]. HSP27
is also an inhibitor of apoptosis by sequestering cytochrome c
when released from the mitochondria, preventing the mito-
chondrial release of second mitochondria-derived activator
of caspases (SMAC), blocking the activation of the prolifera-
tive PI3K-AKT pathway that enables cells to divert energy
consumption toward relieving the ER stress, and stimulating
prosurvival NF-κB signaling [430]. The latter effect is some-
what controversial given the consensus that downregulation
of many NF-κB target genes can be attributed to the HSP-
dependent inhibition of NF-κB activation, suggesting a com-
plicated relationship between the HSF pathway and the
NF-κB pathway.
IRE1, ATF6, and PERK Besides HSF1, downstream events
related to proteotoxic stress are also induced by the IRE1,
ATF6, and PERK. IRE1 has kinase activity and RNAse activ-
ity via which it stimulates autophagy and apoptosis. The cy-
tosolic domain of IRE1 complexes with TRAF2 to activate
ASK1, resulting in prolonged, proapoptotic JNK1 activation.
Autophagy is stimulated by IRE1 via the splicing of XBP1
mRNA, resulting in the accumulation of an active XBP1 tran-
scription factor. XBP1 upregulates the production of
Fig. 10 Activationmechanism of
the ER stress response as a result
of proteotoxic stress. Unfolded
protein detectors IRE1, PERK,
and ATF6 are sequestered by
HSP70A5. Upon proteotoxic
stress due to protein oxidation,
misfolding, or formation of
protein aggregates, HSP70A5 is
recruited toward the misfolded
proteins. The ER stress detectors
are subsequently activated,
leading to the initiation of XBP1,
ATF4, and ATF6 transcription
factor function
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HSP70A5, protein disulfide-isomerase (PDI)P5, HSP40B9,
ubiquit in-conjugating enzyme E2E1, and the ER
degradation-enhancing α-mannosidase-like protein 1
(EDEM1) [435] (Fig. 11) that all aid in refolding and degra-
dation of misfolded proteins, a process termed ER-associated
degradation (ERAD) [436]. ERAD is a form of autophagy
through which terminally misfolded proteins and protein com-
plexes are targeted for proteasomal degradation, eventually
reducing proteotoxic (ER) stress [436]. Additional target
genes of XBP1 include XBP1 and ATF6A as well as several
other genes with a diverse range of functions [435] (Fig. 11).
ATF6 is also activated by proteotoxic stress and initiates
the transcription of chaperones and ERAD-associated genes.
These chaperone genes include HSPA5 (HSP70A5),
HSP90B1, and CRT (calreticulin, CRT). ATF6 additionally
triggers the expression of ERAD-stimulating genes such as
XBP1 , PDI , yea s t De r1 - l i ke p ro t e in (DERL1 ) ,
homocysteine-induced ER-protein (HERP), synovial apopto-
sis inhibitor 1 (SYVN1), and suppressor of Lin-12-like
(SEL1L) [437]. ATF6 also upregulates C/EBP homologous
protein (CHOP, encoded by DDIT3) to promote apoptosis
[436, 438] (Fig. 11).
Activated PERK phosphorylates and activates NRF2 (Sec-
tion 3.1) and EIF2α, resulting in activation of the antioxidant
stress response and general inhibition of translation yet the
selective translation of ATF4mRNA. In turn, ATF4 stimulates
both apoptosis and survival. It upregulates the expression of
proapoptotic proteins such as CHOP, p53-upregulated modu-
lator of apoptosis (PUMA, or BCL2-binding component 3
(BBC3)), GADD34 (or protein phosphatase 1, regulatory sub-
unit 15a (PPP1R15A), tribbles-related protein 3 (TRIB3), and
BIM (BCL2L11) [437]. Survival is promoted via stimulation
of amino acid metabolism, protein (re)folding, and restoration
of redox homeostasis [439, 440] (Fig. 11). The latter function is
achieved via HO-1 upregulation by complex formation with
NRF2 [441]. Interestingly, ATF4 is activated by hypoxia and
plays an important role in resistance to cancer therapy in a similar
fashion to HIF-1 [440]. Interested readers are referred to more
elaborate reviews on ER stress and the UPR [420, 425].
3.5.3 Role of the proteotoxic stress response in PDT
PDT was found to activate HSF [442, 443] and stimulate the
production of HSP70, HSP47, HSP60, and HSP27 [442,
444–450]. Furthermore, high levels of HSP27, HSP60,
HSP70, and HSP90 were linked to reduced susceptibility of
tumor cells to PDT in vitro and in vivo [250, 444, 448, 450,
451]. The cytoprotective properties of HSPs after PDT likely
arise from the alleviation of proteotoxic stress that ensues
protein oxidation. The induction of ER stress by PDT was
studied by Szokalska et al., who showed that porfimer
sodium-PDT leads to extensive protein carbonylation,
polyubiquitination, and widening of the ER lumen [27].
Moreover, PDT induced XBP1 activation and upregulation
of HSP70A5 and calnexin, whereby ERAD was crucial for
the survival of EMT-6 and HeLa cells after PDT in vitro and
in vivo [27]. A microarray looking at the transcriptional re-
sponse of T24 bladder cancer cells to hypericin-PDT showed
significant mRNA upregulation of HSP70A5, 40, 47, 60, 90,
110, CHOP, GADD34, XBP1, PERK, ATF3, and ATF4, pro-
viding compelling evidence for the involvement of HSF1 and
the UPR in response to PDT [124]. A follow-up study by the
same group suggested that PERK-upregulated NOXAwas the
main instigator of tumor cell death after hypericin-PDT-
induced ER stress [452].
Fig. 11 Transcriptional regulation of genes induced byXBP1,ATF6, and
ATF4 in response to proteotoxic stress. XBP1 stimulates protein
(re)folding, ERAD, and amplifies the UPR. ATF6 also promotes protein
(re)folding and ERAD, but also stimulates apoptosis by upregulating
DDIT3 (CHOP). ATF4 ameliorates proteotoxic stress by upregulating
ATF3 and a plethora of DNAJ genes (encoding various isoforms of
HSP40). ATF4 additionally upregulates genes involved in amino acid
metabolism that include, but are not limited to, asparagine synthetase
(ASNS), alanyl-tRNA synthetase (AARS), asparagyl-tRNA synthetase
(NARS), tryptophanyl-tRNA synthetase (WARS), and the cationic amino
acid transporter SLC7A1. ATF4 additionally upregulates proapoptotic
genes BBC3, BCL2L11, DDIT3, PPP1R15A, and TRIB3
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With respect to the antitumor immune response, HSP70 in
particular has been implicated in immune cell modulation af-
ter PDT [199, 422]. Apoptotic cells expressed HSP70 on their
plasma membrane after PDT [445], most likely in an attempt
to stabilize the plasma membrane or chaperone integral mem-
brane proteins [422]. Moreover, HSP70 can bind protein frag-
ments derived from tumor-specific antigens such as mutated,
truncated, or misfolded proteins. When expressed on the plas-
ma membrane or released from necrotic cells, these HSP70/
tumor antigen complexes can be taken up by dendritic cells to
induce their maturation, activation, and migration to lymph
nodes, where they can initiate cross-presentation to naive T-
cells and stimulate the formation of tumor-specific CD8+ cy-
totoxic T cells (reviewed in [199]). A similar mechanism in
favor of dendritic cell activation has been ascribed to CRT (a
downstream gene product of ATF6), which aids in ER protein
folding. When CRT is expressed on the outer leaflet of the
plasma membrane (ecto-CRT), it is associated with the induc-
tion of immunogenic cell death that stimulates antigen presen-
tation and the activation of immune cells. Following
hypericin-PDT (hypericin localizes to the ER), T24 cells
expressed ecto-CRT in a PERK-dependent manner. Moreover,
PERK was essential for the immunogenicity of CT26 cells
treated with hypericin-PDT in vivo [453]. Thus, the
proteotoxic stress response seems to play a key role in medi-
ating an antitumor immune response.
3.5.4 Inhibition strategies for the proteotoxic stress response
and its downstream targets
It may be postulated that inhibition of HSPs would be benefi-
cial when beneficial for PDToutcome given the role of HSPs
in tumor cell survival [422]. However, their role in promoting
the antitumor immune response also suggests that HSP inhi-
bition may be detrimental [199]. Ferrario and Gomer used the
geldanamycin derivative 17-AAG [155] to inhibit the function
of HSP90 (Table 1) during PDT and found a reduction in
protein levels of survivin, VEGF, phospho-AKT, and BCL2.
A higher cure rate and long-term survival were observed in
BA mammary tumor-bearing mice treated with PDT com-
bined with 17-AAG [250, 252]. HSP70 inhibition with the
bacterial cytotoxin SubA fused to EGF [160], (Table 1) was
recently shown to augment the efficacy of porfimer sodium-
PDT in human SW-900 lung cancer cells and DU-145 prostate
cancer cells as a result of increased ER stress [454]. Taken
together, these results point toward the beneficial effect of
HSP inhibition in the enhancement of PDT efficacy. Besides
17-AAG, other HSP90 inhibitors are available and include
different geldanamycin derivatives, although these may be
associated with liver toxicity [455], as well as the synthetic
small molecules CNF-2024/BIIB-021, NVP-AUY922, SN-
X5422, and STA-9090 (Table 1), which are undergoing clin-
ical trials [156–159, 456]. However, inhibition of HSP90
typically exacerbates proteotoxic stress that induces HSP70
proteins [457] and may therefore alleviate any beneficial ef-
fects of these agents in terms of tumor cell death.
Alternatively or in addition to HSP90 inhibition, HSP70 in-
hibitors are also available. Schlecht et al. recently demonstrated
the inhibition of HSP70 and HSC70 (a constantly expressed
isozyme of HSP70) using VER-155008, a compound that binds
the nucleotide binding domain of these proteins and reduces their
ATPase activity (Table 1). In RNAi knockdown experiments, it
was shown that concomitant inhibition of HSP70 and HSC70
was necessary to induce tumor cell death [161]. Amore effective
approach to completely abolish the heat shock response is to
block HSF1 activity. KRIBB11 (N2-(1H-indazole-5-yl)-N6-
methyl-3-nitropyridine-2,6-diamine) is an HSF1 inhibitor that
blocks the association between HSF1 and positive elongation
factor b, which is required for HSF1 transcriptional activity
(Table 1). Accordingly, KRIBB11 was very effective in
preventing HCT-116 tumor growth in nude mice [458]. Based
on these results, inhibitors of the HSF pathway could be used to
elucidate the role of this pathway in PDTandmay provide prom-
ising approaches to improve PDT efficacy.
During ER stress, cells deal with the accumulation and
aggregation of carbonylated proteins by polyubiquitination
and proteasomal degradation. Therefore, Szokalska et al. in-
vestigated whether inhibition of the proteasome could exacer-
bate ER stress and increase the extent of cell death after PDT.
Indeed, porfimer sodium-PDT on EMT-6 and HeLa cells
pretreated with 4 ng/mL bortezomib (binds and inhibits the
catalytic center of the 26S proteasome [162], Table 1) for 24 h
increased the accumulation of carbonylated proteins and
disrupted ERAD, leading to an increased sensitivity of cells
to PDT [27]. Similar results were obtained for verteporfin-
PDT in combination with bortezomib (2 mg/kg) in a PC-3
mouse xenograft model [459]. Thus, these results attest to
the utility of pharmacological interventions in proteasome
function as a means to augment ER stress and improve the
therapeutic efficacy of PDT. Pharmacological inhibition of
IRE1 and ATF6 (but not PERK) is possible with 4-
phenylbutyric acid analogs (Table 1), although the exact
mechanism has not been elucidated [163]. With respect to
PERK, inhibition is possible with the synthetic compound
GSK2656157 (Table 1), which competes with ATP to bind
PERK specifically, and thus inhibits its kinase activity [164].
However, none of these UPR-inhibiting compounds have
been investigated in combination with PDT.
3.5.5 Concluding remarks
Proteotoxic stress appears to be a primary response to PDT
regardless of cell type and PDT strategy. The degree to which
this response is triggered depends somewhat on the photosen-
sitizer localization insofar as ER-localizing photosensitizers
such as hypericin are more effective in inducing the UPR than
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photosensitizers that accumulate in other intracellular venues.
While the functional outcome of this pathway may be both
protective and destructive in tumor cells, the protective effects
of the proteotoxic stress response can be pharmacologically
blocked to promote tumor cell death. Inhibition of HSP70 and
HSP90 was shown to increase the efficacy of PDT, as did
inhibition of the proteasome by exacerbating ER stress. The
HSF pathway is an essential component of the UPR in re-
sponse after PDT. Given its reported induction by hypoxia
and its constitutive activation in tumor cells [460], the UPR
may protect tumors against anticancer therapies [424] such as
PDT. Disrupting the cytoprotective effects of the UPR or in-
terfering with the function of chaperones has been shown to
enhance proteotoxic stress and stimulate cellular demise after
PDT. Thus, the proteotoxic stress pathway is an important and
feasible target for pharmacological interventions to enhance
the therapeutic efficacy of PDT.
4 Concluding remarks
Tumor cells have the intrinsic ability to adapt to potentially
harmful situations, such as those induced by chemotherapy, ra-
diotherapy, and PDT. With respect to PDT, the activation of
NRF2, NF-κB, HIF1, ASK1, HSF1, IRE1, PERK, and ATF6
and the effects of their downstream protein and gene targets have
been reviewed. Together, these transcription factors and kinases
facilitate the survival of tumor cells that suffer from a disrupted
redox balance, low oxygen availability, apoptotic signaling, and
oxidative damage to proteins.
The pathways that have the highest potential for pharmaco-
logical inhibition with the aim to improve the therapeutic effi-
cacy of PDT are those from which no proapoptotic stimuli
emerge. In that respect, blocking the NRF2, HIF1, and HSF1
pathways holds the highest potential to reduce the extent of
tumor cell survival post-PDT. This is reflected by the substan-
tial amount of evidence in which the inhibition of one or more
of the downstream protein products (e.g., HO-1, COX-2,
HSP70) from these pathways has led to increased efficacy of
PDT. Unfortunately, the conclusion is not that straightforward
regarding the ASK1 pathway. The ASK1 signaling axis mainly
promotes survival via transient JNK1 and p38MAPK activity
and their induction of the AP-1 transcription factors. However,
upon prolonged oxidative stress and corollary TNF-α signal-
ing, JNK1 has potent proapoptotic activity. Thus, selective in-
hibition of p38α/β, but not the complete ASK1 signaling cas-
cade, may be therapeutically beneficial for PDT, as is evi-
denced by the available literature on this topic (Table 1). The
transcriptional events emanating from the activated UPR tran-
scription factors IRE1, ATF6, and PERK are also challenging
with respect to designing a pharmacological inhibition strategy.
Whereas no proapoptotic signaling appears to arise from IRE1,
both ATF6 and PERK promote apoptosis via the induction of,
e.g., CHOP. Moreover, the multitude of potential target genes
and effects make it arduous to predict the results of an inhibi-
tion strategy in conjunction with PDT. Thus, there is an explicit
need for further investigations regarding the importance of
these particular pathways in the cellular response to PDT. Inhi-
bition of the NF-κB pathway appears unwise given its strong
proinflammatory function and its potential to induce pro-
grammed cell death. It is probable that some downstream tar-
gets of this pathway are very strong inducers of tumor cell
survival (i.e., COX-2 and survivin), yet completely abolishing
this pathway has not produced convincing evidence that phar-
macological inhibition is feasible in combination with PDT.
Thus, the ambiguous downstream effects of the AP-1, UPR,
and NF-κB pathways illustrate an obvious pitfall in applying a
pharmacological inhibition strategy for these signaling cas-
cades, since blocking a particular pathway also diminishes
any proapoptotic effects of that pathway. A less obvious risk
is the use of a compound that is capable of scavenging ROS
that are produced during the photoexcitation of the intratumoral
photosensitizers. This reduces the effective amount of PDT-
produced ROS required to induce cell death. Therefore, an
extensive photochemical characterization of the compound of
interest should be performed prior to further experimentation
regarding pathway inhibition and PDTefficacy. Finally, when a
suitable compound has been selected and has yielded favorable
outcomes, a careful investigation of the prolonged antitumor
immune response should be conducted. Many of the pathways
discussed in this review induce immune-modulating and angio-
genic factors that may negatively affect the antitumor immune
response, which is required to facilitate effective removal of the
tumor.
Many of the key signaling proteins discussed in this review
are constitutively active in tumors and may therefore contribute
to a natural resistance to PDT. Therefore, tumors that typically
respond poorly to PDT such as nasopharyngeal carcinomas,
bladder tumors, and extrahepatic cholangiocarcinomas may be
rendered substantially more susceptible to PDTwhen these adap-
tive pathways are inhibited. Investigations regarding the consti-
tutive activation of these pathways in the abovementioned tumor
types are highly valuable in selecting a suitable pharmacological
inhibition strategy.
In conclusion, the promising investigations in which sur-
vival pathway inhibitors are used as (neo)adjuvant agents in
PDT are of high importance to cancer patients. A higher PDT
efficacy will lead to better disease management, lower mor-
bidity, and prolonged patient survival.
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